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APPENDIX – II
Canadian Cardiovascular Society Classification Class :
I “Ordinary physical activity does not cause angina,”  such as walking or climbing
stairs.Angina occurs with strenuous, rapid, or prolonged exertion at work or
recreation.
II  “Slight limitation of ordinary activity.”
Angina occurs on walking or climbing stairs rapidly; walking uphill ,under emotional
stress; or only during the few hours after awakening. Angina occurs on walking >2
level blocks and climbing >1 flight of ordinary stairs at normal pace and under normal
conditions.
III “Marked limitation of ordinary physical activity.”
Angina occurs on walking 1 to 2 level blocks and climbing 1 flight of ordinary stairs
under normal conditions and at normal pace.
IV “Inability to carry on any physical activity” without discomfort anginal symptoms
may be present at rest.
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PROFORMA
Name:
IP number:
Age:
Sex:
Weight:
Diagnosis :
Class of angina :
HISTORY:
Medical history:
1.Hypertension
2.Diabetes mellitus
3.Asthma
4. Seizure disorder
5.Bleeding diathesis.
Surgical history:
1.coronary angiography
2. CABS
3.Pacemaker implantation.
Drug history :
1. Aspirin/clopidogrel /statin
2. Beta blockers/ACE inhibitors / ARB / nitrates .
Other history :
Smoking/ alcohol and substance abuse .
Basic investigations:
Hb% TC DC ESR BT CT
Base line
After 1 month
After 3 months
Liver Function Test :
Other investigations:
Blood sugar Blood urea Serum
creatinine
Serum
electrolytes
Baseline
After 1 month
After 3 months
ECG findings :
HR PR interval QT interval
Baseline
After 1 month
After 3 months
Direct
bilirubin
Indirect
bilirubin
Total
bilirubin
ALT AST ALK
PHOS
Base line
After 1 month
After 3 months
ECHO findings:
Class of angina :
Adverse effects :
1.Bradycardia
2. Severe hypotension
3.Heart Failure
4. Heart block 1/2/3 degree block.
5. Liver dysfunction.
EFFICACY AND SAFETY OF IVABRADINE AS AN ADD-ON TO ATENOLOL
IN PATIENTS WITH CHRONIC STABLE ISCHEMIC HEART DISEASE
ABSTRACT:
INTRODUCTION:
Coronary artery disease is the leading cause of morbidity and mortality. Heart rate is
the important key factor for determining the cardiac output ,myocardial oxygen demand
and coronary blood flow . By the year 2020 , WHO predicts 13.2% death due to CAD . In
india , 11% of urban population and 7% of the rural population had the prevalence of
IHD. Reduction in heart rate is the main stay of treatment for preventing and treating the
cardiovascular complications due to IHD. Pharmacotherapy of IHD are the conventional
drugs like nitrates, beta blockers and calcium channel blockers . Due to the interactions
with other drugs and adverse effects of the conventional drugs ,the management of IHD
focused on novel targets . Ivabradine is a novel specific and selective If current inhibitor
which slows the diastolic depolarization by acting on the SA node.
OBJECTIVE :
Efficacy and safety of Ivabradine as an add-on to atenolol in patients with chronic
stable ischemic heart disease .
MATERIALS AND METHODS:
Interventional ,open label ,prospective clinical study was done over a period of 1
year (April 2014 to May 2015).Single centered study conducted in 50 patients in the Out
patient Department of cardiology ,Tirunelveli Medical College Hospital ,
Tirunelveli.Primary endpoints noted were reduction in resting heart rate using 12 lead
ECG and improvement in Canadian cardiovascular  society (CCS)class of angina
grading. Secondary end points were improvement in ejection fraction(EF) using
echocardiography,improvement in left ventricular function(LVF) using echocardiography
and improvement in quality of life score using SAQ .
RESULTS:
The demographic data concerning the patient’s age, sex, weight, vitals, hemodynamic
and laboratory parameters were statistically assessed at the baseline. Ivabradine in
reducing the heart rate at  the end of  1month (86.60±9.16) (p<0.0001) and at the end of
3 months (81.82±8.37)( p<0.0001) when compared with baseline (93.08±11.67). CCS
class of grade of angina also improved at the end of one month and 3 months compared
with baseline .Grade IV ( 3 – 0 - 0), grade III(7  3 -1) and grade II( 40 -8 - 9).
Study drug improved the LV dysfunction . After treatment with tab.Ivabradine , there
were no patients with severe LV dysfunction at the end of 1 and  3 months when
compared with 5 patients at the baseline.After treatment with study drug, moderate LV
dysfunction was reduced to 20 patients at the end of 1 month and 6 patients at the end of
3 months when compared with 35 patients at the baseline. After treatment with study
drug the improvement in ejection fraction% was( 45.48±5.03) (p<0.001) at the end of one
month and (49.08±4.17) (p<0.001) three months compared with the
baseline(41.36±6.23). Improvement in quality of life also assessed with SAQ
questionnaire . Adverse drug reactions reported during the study was mild and no patients
were withdrawn from the study due to adverse drug reactions and no patients experienced
serious adverse drug reactions.
CONCLUSION :
Ivabradine is safe and  effective in preventing and treating further anginal attacks in
patients with chronic stable ischemic heart disease  already on atenolol therapy.
KEYWORDS: Ivabradine, If current ,Ischemic Heart Disease, Heart Rate, Angina,
Ejection fraction .

1INTRODUCTION
Coronary heart disease is the leading cause of mortality and morbidity in
developing countries and chronic stable angina pectoris is a primary symptom and the
first clinical manifestation in upto 50% of patients1. Angina pectoris is characterized
by substernal discomfort, heaviness, or a pressure-like feeling, which may radiate to
the jaw, shoulder, back, or arm and which typically lasts several minutes2 .Angina
pectoris is caused by myocardial ischemia due to an imbalance   between myocardial
oxygen requirements and myocardial oxygen supply. The former may be elevated by
increase in heart rate and contractility ,the latter is determined by coronary blood flow
and coronary arterial oxygen content3.
Heart rate is an important contributor in the pathophysiology of both coronary
artery disease (CAD) and heart failure (HF).Heart rate is being recognised as a
modifiable risk factor in patients with cardiovascular disease4.  Elevated  heart rate
increases myocardial oxygen demand and limits tissue perfusion ,the latter by
shortening the duration of diastole during which most myocardial perfusion occurs.
5Pharmacotherapy for IHD is to reduce the frequency of anginal episodes, myocardial
infarction, and coronary death. To achieve maximum benefit from medical therapy for
IHD, it is  necessary to combine agents from different classes and titrate the doses as
guided by the individual profile of risk factors, symptoms, hemodynamic responses,
and side effects. 6In current clinical practice ,however many patients with chronic
stable IHD require treatment with more than one anti-anginal drug in addition to
nitrates, beta-blockers  or calcium channel blockers(CCB)7.
2Ivabradine is a novel specific and selective heart rate lowering agent that acts in
sino-atrial node(SA) cells by selectively inhibiting the cardiac pacemaker in a dose
dependant manner.8If current has atypical or funny properties compared to other
current systems such as a mixed Na +-K+ inward movement activated on
hyperpolarization and modulated by autonomic nervous system. It is one of the most
important  ionic current for regulating the pacemaker activity in the SA node.
Ivabradine reduces the slope of diastolic depolarization in these cells and lowers the
heart rate at rest and during exercise.2,9
Beta blockers ,unlike ivabradine , reduce If activation by decreasing the
sympathetic activity and cAMP formation, resulting in a lower HR. Left ventricular
function and ventricular remodeling may be improved  with If inhibition with beta
blockers like atenolol . If inhibition with ivabradine does not alter myocardial inotropy
or left ventricular function and reduces the remodeling process thus supporting cardiac
output and coronary outflow during exercise.6 Beta blockers have been used only in a
limited manner because of hemodynamic or pulmonary intolerance. Beta blockers
should be avoided in patients with reactive airway disease (asthma) or with SA or AV
nodal dysfunction or in combination with other drugs that inhibit AV conduction like
verapamil.10
CCBs bind to and inhibit L-type calcium channels, reducing calcium influx into
cells. Intracellular calcium deprivation relaxes smooth muscle cells, causing
vasodilation in the peripheral and coronary beds and increased coronary blood
flow.11CCB s can produce negative chronotropic effect thereby reduce the heart rate .
3However CCBs may cause reflex tachycardia, headache and edema and limit their
usefulness in chronic stable angina12.
There is still limited clinical trials related to Ivabradine and its combination with
atenolol , which show its anti-anginal and anti-ischemic efficacy and safety in chronic
stable ischemic heart disease. Thus the  present study  is aimed to evaluate the anti-
anginal and anti-ischaemic efficacy  and safety of the selective If current inhibitor
ivabradine in patients with chronic stable angina pectoris already  receiving  atenolol,
beta blocker  therapy.
4REVIEW OF LITERATURE
I. HISTORY OF ANGINA PECTORIS :
The concept of circulation was first presented to the Royal College of
Physicians, London, and published in 1628 as Exercitatio anatomica de motu
cordis et sanguinis in animalibus (An anatomical disputation of the movement of
the heart and blood in animals) .Harvey stated that the blood is driven into a
circular motion and that it moves perpetually and that this is the action or function
of the heart which the heart performs by means of its pulse. On July 1768, William
Heberden appropriated the term angina ( Latin word meaning "strangling") and
presented a seminar on  "Some Account of a Disorder of the Breast" to the Royal
College of Physicians, London, in which he stated that there was  a disorder of the
breast marked with strong and peculiar symptoms ,a sense of strangling and
anxiety with which it was improperly be called angina pectoris. 13
II. MAGNITUDE OF THE PROBLEM:
In many developed countries CHD is the largest public health problem.
According to the global burden, by the year 2020 WHO predicts that among 65
million deaths 32% death due to cardiovascular complications and 13.2% death due to
CHD .14In western countries the propotional mortality ratio is 30%death in males and
25% death in females due to CHD. According to a survey related to the prevalence of
CAD and coronary risk factors  ,prevalence of coronary artery disease in urban
population is approximately 11% and rural population is around 7% across India.15
5III. DEFINITION OF CHRONIC STABLE ANGINA:
Chronic stable angina pectoris refers to the predictable occurrence of a pressure or
a choking sensation in the chest or adjacent areas caused by myocardial ischemia in
association with physical or emotional stress and prompt relief of these symptoms
with rest or sublingual nitroglycerin (glyceryl trinitrate). An imbalance between
myocardial oxygen (O2) demand and supply is responsible for myocardial ischemia
and anginal pain.In most patients who have chronic stable angina, the underlying
lesion responsible for reduced myocardial blood flow(O2 supply) during periods of
increased demand is severe atherosclerotic narrowing of one or more coronary
arteries, which paradoxically constrict during exercise owing to endothelial
dysfunction.16
IV. NEUROMECHANISMS  OF CARDIAC PAIN:
The mechanisms of cardiac pain and the neural pathways assumed that angina
pectoris results from ischemic episodes that excite chemo-sensitive and mechano-
sensitive receptors in the heart. Stimulation of both of these receptors results in the
release of adenosine, bradykinin, and other substances that excite the sensory ends of
the vagal afferent and sympathetic fibers. The afferent fibers traverse the nerves that
connect to the upper five thoracic sympathetic ganglia and upper five distal thoracic
roots of the spinal cord. Impulses are transmitted by the spinal cord to the thalamus
and then to the neocortex. Data from murine vanilloid receptor-1 gene knockout
model studies have identified the VR1, an important sensor for somatic nociception
situated on the sensory nerve endings of the heart and have suggested that VR1
functions as a transducer of myocardial tissue ischemia.
6Within the spinal cord, cardiac sympathetic afferent impulses may unite with
impulses from somatic thoracic structures (T2 ,T3 and T4), which may be the basis
for the pain referred to the chest. In addition, cardiac vagal afferent fibers synapse in
the nucleus tractus solitarius of the medulla and then descend to excite the upper
cervical spinothalamic tract cells, which may contribute to the anginal pain
experienced in the neck and jaw.17
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8V. DIFFERENT TYPES OF ANGINA:19
Five different kinds of angina have been identified:
 stable angina
 unstable angina
 Varient angina or primary angina
 microvascular angina or syndrome X
 silent angina and
 atypical angina
with the two most common being stable angina and unstable angina.
 Stable angina ( effort induced angina ):
Otherwise called classical angina or angina on exertion .  This is the most common
type of angina and it is either due to reduced oxygen supply or increased oxygen
demand to myocardium.The ischemic attack occurs on exertion but there is no
symptom at rest . These patients usually present with ST-segment depression on the
electrocardiogram suggesting subendocardial ischemia.
 Unstable angina :
Otherwise called crescendo preinfarction or acute coronary syndrome.There is
dislodging of a coronary plaque that triggers the local platelet aggregation and
thrombosis which results in total or partial occlusion of coronary blood vessels. There
is increased vascular tone leading to angina at rest . These patients are often prone to
develop an acute myocardial infarction as a result of plaque rupture, thrombosis, and
coronary vasoconstriction or spasm20. Less common kinds of angina include variant
angina ,microvascular angina, silent angina and atypical angina.
9 Variant Angina:
Variant angina is otherwise called (Prinzmetal angina).Coronary spasm may
lead to ST-segment elevation on the electrocardiogram. The exact mechanism
responsible for coronary spasm has been due to number of vasoconstrictor substances
including sympathomimetic amines such as norepinephrine or epinephrine, serotonin,
histamine, endothelin, thromboxane A2 and acetylcholine act on G protein–coupled
receptors will cause an increase in extracellular K+ or Ca2+ would result in
membrane depolarization and vasoconstriction. This has also been implicated as
causing coronary vasospasm.21
 Microvascular angina :
Some patients with angiographically normal coronary arteries have a positive
exercise stress test with ST-segment depression on the electrocardiogram and
perfusion defects indicative of myocardial ischemia and classical angina pectoris. This
condition is often termed as “cardiac syndrome X” . The exact etiology of this
syndrome is not certain. In this the symptoms of ischemia are absent but
investigations like ECG ,echocardiography and other investigations show evidence of
ischemia.
 Silent angina: Patients with CAD (particularly patients with diabetes) may
have ischemia without symptoms. Ischemia is evidenced by transient asymptomatic
ST-T abnormalities seen during 24-h Holter monitoring. Silent ischemia and angina
pectoris may coexist, occurring at different times. Radionuclide studies can sometimes
document asymptomatic myocardial ischemia during physical or mental stress.
Prognosis depends on severity of CAD.
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 Atypical angina
There may be a vague discomfort in the chest. Patient may experience shortness
of breath, feel tired or nauseous, have indigestion or pain in the back or neck. Women
are more likely than men to have feelings of vague chest discomfort.22
VI. GRADING OF ANGINA PECTORIS :
Canadian Cardiovascular Society Classification Class : 23
I “Ordinary physical activity does not cause angina,” such as walking or climbing
stairs.Angina occurs with strenuous, rapid, or prolonged exertion at work or
recreation.
II “Slight limitation of ordinary activity.”
Angina occurs on walking or climbing stairs rapidly; walking uphill ,under emotional
stress; or only during the few hours after awakening. Angina occurs on walking >2
level blocks and climbing >1 flight of ordinary stairs at normal pace and under normal
conditions.
III “Marked limitation of ordinary physical activity.”
Angina occurs on walking 1 to 2 level blocks and climbing 1 flight of ordinary stairs
under normal conditions and at normal pace.
IV “Inability to carry on any physical activity” without discomfort anginal symptoms
may be present at rest.
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NYHA classification of angina:21
NYHA
Class Symptoms
I No symptoms and no limitation with ordinary physical activity
e.g. no shortness of breath when walking, climbing stairs etc.
II Mild symptoms  and slight limitation during ordinary activity
III Marked limitation in activity due to symptoms.
even   less-than-ordinary activity
IV Severe limitations in physical activity even at rest.
VII. PATHOPHYSIOLOGY OF CHRONIC STABLE ANGINA :
For an  understanding the pathophysiology of myocardial ischemia is the balance
between myocardial oxygen demand and blood supply . The major determinants of
myocardial oxygen demand  are heart rate, myocardial contractility, and myocardial
wall tension. An adequate supply of oxygen is determined by the inspired level of
oxygen, pulmonary function, and hemoglobin concentration. The myocardium
requires a satisfactory level of oxygen-carrying capacity of the blood and an adequate
level of coronary blood flow. In normal conditions ,the myocardium will control the
supply of oxygen-rich blood to prevent underperfusion of myocytes. Thereby it will
prevent  the subsequent development of ischemia and infarction. Blood flows through
the coronary arteries in a phasic fashion during diastole.24
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a)Angina Caused by Increased Myocardial O2 Requirements :
Also called demand angina .The myocardial O2 requirement increases most commonly
due to restricted O2 supply. Hurrying, emotion and mental stress precipitate angina by
increased hemodynamic and catecholamine responses to stress, increased adrenergic
tone and reduced vagal activity. The combination of physical exertion and emotion in
association with sexual activity may precipitate angina pectoris. Anger may produce
constriction of coronary arteries with pre-existing narrowing, without necessarily
affecting O2 demand. Other precipitants of angina include physical exertion after a
heavy meal and the excessive metabolic demands imposed by fever, thyrotoxicosis,
tachycardia from any cause, and hypoglycemia.
b)Angina Caused by Transiently Decreased O2 Supply:
Also termed  as supply angina . Transient reductions in O2 supply has suggested that it
occurs not only in unstable angina but also in chronic stable angina. In the presence of
organic stenoses, platelet thrombi and leukocytes may elaborate vasoconstrictor
substances, such as serotonin and thromboxane A2. Also, endothelial damage in
atherosclerotic coronary arteries decreases production of vasodilator substances and
may result in an abnormal vasoconstrictor response to exercise and other stimuli.By
reducing the lumen of the coronary arteries, atherosclerosis limits the perfusion when
the demand for flow is augmented, as occurs during exertion or excitement. When the
luminal reduction is severe, myocardial perfusion in the basal state is reduced.
Coronary blood flow also can be limited by spasm ,arterial thrombi and coronary
emboli as well as by ostial narrowing due to aortitis. Congenital abnormalities such as
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the origin of the left anterior descending coronary artery from the pulmonary artery
may rarely cause myocardial ischemia and infarction in adults.25
FIGURE 2
PATHOPHYSIOLOGY OF  CHRONIC STABLE ANGINA24
VIII. CONTROL OF CORONARY BLOOD FLOW:
I. Local Metabolic Feedback Control:
An intrinsic local mechanism controls coronary blood flow to match changes
in myocardial O2 consumption. The augmented O2 delivery restores myocardial O2
tension toward the normal operating point in a negative feedback manner. When
myocardial O2 consumption increases, there is an incipient decrease in cardiac O2
tension, which results in a local vasodilator signal that increases coronary blood flow
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and O2 delivery to the myocardium.. There have been several hypotheses about local
metabolic control of coronary blood flow.
a. the adenosine hypothesis
b. the role of K + ATP channels; and
c. the role of O2 and carbon dioxide .
a)Adenosine Hypothesis:
The adenosine hypothesis proposes that adenosine is released from cardiac myocytes
,if myocardial O2 tension falls . Adenosine then crosses the interstitial space to act on
adenosine receptors. It causes hyperpolarization of coronary vascular smooth muscle
cells and causes dilatation of vascular smooth muscle.The resulting increases the
coronary blood flow, which restores the balance between oxygen demand and
supply.It is well established that ischemic or hypoxic myocardium releases adenosine,
which acts as a pathophysiologic vasodilator.26
b)Role of K +ATP Channels:
K +ATP channels are found in the membranes of cardiac and coronary vascular
smooth muscle cells . The experiments with hypoxia and ischemia interpreted as
glibenclamide blunting the vasodilatory effects of adenosine . Therefore, blocking of
K +ATP channels with glibenclamide results in a decrease in coronary blood flow.
c)Role of Oxygen and Carbon Dioxide:
A hypothesis is that blood flow is primarily controlled by precapillary arterioles
upstream from where the bulk of O2 and CO2 exchange occurs. Thus, the blood inside
the arteriole has O2 and CO2 tensions that are close to the arterial level. Coronary
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blood flow certainly responds to changes in arterial blood O2 content. A correlation
between coronary blood flow and the synergistic effects of O2 and CO2 can be made
when myocardial O2 consumption is increased by increase in coronary flow. For
example, anemia  increases coronary blood flow, but coronary venous O2 tension is
little changed, demonstrating a good match between O2 delivery and myocardial O2
consumption by local metabolic control.27
II. Control of Flow by the Endothelium :
Endothelial cells lines the inner surface of the cardiovascular system .The
endothelium produces vasoactive substances (eg, nitric oxide, prostacyclin,
endothelin-1, epoxy eicosatrienoic acids) and responds to circulating factors (eg,
epinephrine, serotonin). The overall function of the endothelium is to increase the
blood flow through the arteries.Any damage to the endothelium resulted in
vasoconstriction . Nitric oxide (NO) is the main mediator of vasodilation which is
released physiologically through the parasympathetic neural stimulation. NO diffuses
as a gas from the endothelium to the surrounding vascular smooth muscle cells where
it induces a cyclic guanosine monophosphate (cGMP)– dependent muscular
relaxation. In addition to NO, another potent vasodilator is prostacyclin, which  is
released by the endothelium involved in the normal vasodilation at rest .
III. Control by the Autonomic Nervous System:
i. Parasympathetic (Muscarinic) Receptor Control :
Vagal stimulation has a vasodilatory effect in the coronary bed by releasing NO .
In addition to a direct effect on the coronary bed, increased parasympathetic tone
reduces heart rate, arterial pressure, and inotropy. Altogether it reduces the oxygen
demand of the myocardium . This effect is reproduced by administration of
16
acetylcholine and is blocked by atropine. It is well documented that parasympathetic
system by releasing acetylcholine is responsible for coronary vasodilation .
ii. Alpha Adrenergic Receptor Control :
The stimulation of cardiac sympathetic nerves markedly increases coronary blood
flow due to the increased metabolic demand induced by the increase in workload
(heart rate, contractility and LV wall stress) resulting from catecholamine release.
Similarly, direct stimulation of α1-adrenergic receptors with pharmacologic agonists
can provoke vasoconstriction in coronary vessels. An important consequence of the α-
adrenergic–mediated vasoconstriction in a context of increased workload is an
increase in oxygen extraction which might be particularly relevant during exercise.
The α-adrenergic tone of the coronary arteries can be activated by stimulation of
reflex pathways, such as carotid baroreceptors upon carotid sinus hypotension, as well
as by direct sympathomimetic stimulation. Similarly, stimulation of the carotid
chemoreceptor, pulmonary inflation reflex, and arterial baroreceptor hypertension
induce coronary vasodilation that results from a withdrawal of the α-adrenergic tone,
potentially with a smaller vagal component contributing to the vasodilation.28
iii. Beta -Adrenergic Receptor Control :
Stimulation of the β-adrenergic receptors achieves coronary vasodilation through
two mechanisms. First by Binding of the receptors in the coronary vessel itself will
stimulate a Gs protein–mediated relaxation of the vascular smooth muscle cells.
Second by binding of the receptors on the cardiac cells will stimulate a Gs protein–
mediated increase in contractility, which, together with the increase in heart rate, will
increase the metabolic demand and activate the recruitment of the coronary blood flow
reserve through adenosine release. Patient treated with β-blockers will have reduced
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coronary blood flow and exacerbated coronary vasospasm. However, the negative
inotropy and reduction of heart rate following administration of β-blockers markedly
reduce the risk of exercise-induced angina and provide protection following
myocardial infarction and are used widely in patients with ischemic heart disease and
hypertension.29
IV. Coronary Microcirculation:
Individual coronary resistance arteries are a longitudinally distributed network and
the mechanisms controlling  the resistance in these arteries is variable. These vessels
dilate in  co-ordinated  manner so that they are able  to meet the demands of  the distal
vascular bed  . This is done by shear stress mediated control of the blood vessels or
through myogenic control.
The resistance vessels are divided into resistance arteries and arterioles. The
arteries are regulated by shear stress and myogenic response whereas the arterioles are
mainly controlled by local metabolic factors and they regulate the perfusion of
coronary capillary bed. Epicardial arteries  with a diameter greater than  400 micron
are mainly regulated by shear stress. The capillary density is considerably higher in
the sub endocardium than the epicardium.
V. Myogenic Control:
This is a mechanism by which vessels dilate in response to decrease in pressure
and constrict when the pressure increases. It is due to the tone of smooth muscle. It is
believed to be due to the activation of the L type calcium channels.It occurs mainly in
arterioles<100 micron diameter and is an important mechanism in coronary
autoregulation.
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Kuo and colleagues have shown flow-induced dilatation of coronary  vessels30.
This is mediated by NO and hence endothelium dependent. Endothelium Dependent
Hyperpolarising factor ,an arachidonic acid metabolite primarily regulates epicardial
conductance vessels.
FIGURE 3
CORONARY COLLATERAL CIRCULATION
The resistance vessels are controlled by Nitric oxide.   EDHF may be
upregulated during acquired disease states when Nitric oxide is deficient and serve as
a compensatory mechanism assisting vasodilatation.
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VI. CORONARY ATHEROSCLEROSIS:
Atherosclerosis is a chronic, lipid-driven inflammatory disease of the arterial wall
leading to multifocal plaque development  predominantly at predilection sites
characterized by low and oscillatory endothelial shear stress (bifurcations, inner wall
of curvatures) and preexisting intimal thickenings31.
Epicardial coronary arteries are the major site of atherosclerotic disease. The
major risk factors for atherosclerosis are high levels of plasma low-density lipoprotein
(LDL), low plasma high-density lipoprotein (HDL),cigarette smoking, hypertension,
and diabetes mellitus  that disturb the normal functions of the vascular endothelium.
Functional changes in the vascular milieu ultimately result in the subintimal
collections of fat, smooth muscle cells, fibroblasts, and intercellular matrix that define
the atherosclerotic plaque. This process develops at irregular rates in different
segments of the epicardial coronary artery and leads eventually plaque formation.
There is also a predilection for atherosclerotic plaques to develop at sites of
increased turbulence in coronary flow, such as at branch points in the epicardial
arteries. When a stenosis reduces the diameter of an epicardial artery by 50%, there is
a limitation of the ability to increase flow to meet increased myocardial demand.
When the diameter is reduced by ~80%, blood flow at rest may be reduced, and
further minor decreases in the stenotic orifice area can reduce coronary flow
dramatically to cause myocardial ischemia at rest or with minimal stress .A thrombus
composed of platelet aggregates and fibrin strands traps red blood cells and can reduce
coronary blood flow, leading to the clinical manifestations of myocardial ischemia.
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The location of the obstruction influences the quantity of myocardium. This
determines the severity of the clinical manifestations. Thus, critical obstructions in
vessels, such as the left main coronary artery and the proximal left anterior descending
coronary artery, are particularly dangerous. Chronic severe coronary narrowing and
myocardial ischemia frequently are accompanied by the development of collateral
vessels, especially when the narrowing develops gradually. When well developed,
such vessels can by themselves provide sufficient blood flow to sustain the viability of
the myocardium at rest but not during conditions of increased demand.32
VII. RISK FACTORS FOR IHD :33
Major independent risk factors:
 Advancing age
 Cigarette smoking
 Diabetes mellitus
 Hypertension
 Elevated TC , LDL-C
 Low HDL-C
Conditional risk factors :
 Elevated serum lipoprotein (a)
 Elevated serum triglycerides
 Prothrombotic factors(fibrinogen)
 Elevated serum homocysteine
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 Inflammatory markers (CRP)
Predisposing risk factors ;
 Ethnic characteristics
 Family history of premature coronary heart disease
 Physical inactivity
 Abdominal or central obesity
 Psychological factors.
VIII. SYMPTOMS OF ISCHEMIC HEART DISEASE :
The primary manifestation of ischemic heart disease is angina pectoris . It does
not depend on the type of angina and the causal factors involved. Typically, the pain
of angina occurs retrosternally and may manifest as a crushing, burning, or squeezing
type of discomfort. The discomfort  can be associated with shortness of breathe,
nausea, diaphoresis, generalized weakness, and a fear of impending death.The pain
may spread to the lower part of the neck and radiate down the left arm or either arm .
The pain may be mild or intense and lasting for 5 to 10 minutes and is relieved
rapidly by the administration of sublingual nitroglycerin . If nitroglycerin tablets do
not relieve the pain, the pain is likely the result of an ongoing myocardial infarction or
is from an extracardiac source. Chemical mediators such as adenosine, which is
known to be released in large quantities during ischemia. Myocardial ischemia also
appears to occur in cases without the symptoms of chest pain, known as silent
ischemia. Anginal pain may occur in the absence of myocardial ischemia as a result
of esophageal spasm or some other form of gastrointestinal disorder.
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IX. EVALUATION OF IHD :
1. PHYSICAL EXAMINATION:
The physical examination in patients with stable angina are often
asymptomatic. However, because of the increased risk of ischemic heart disease in
patients with diabetes and/or peripheral arterial disease, clinicians should search for
evidence of atherosclerotic disease at other sites, such as an abdominal aortic
aneurysm, carotid arterial bruits, and diminished arterial pulses in the lower
extremities. The physical examination also should include a search for evidence of
risk factors for atherosclerosis such as xanthelasmas and xanthomas. Central obesity
may indicate that the patient has the metabolic syndrome .There also may be signs of
anemia, thyroid disease, and nicotine stains on the fingertips from cigarette smoking.
Evidence for peripheral arterial disease should be sought by evaluating the pulse
contour at multiple locations and comparing the blood pressure between the arms and
between the arms and the legs (ankle-brachial index)
 Palpation may reveal cardiac enlargement and abnormal cardiac impulse .
 Auscultation  of the chest can reveal arterial bruits, a third and/or fourth heart
sound, and an apical systolic murmur due to mitral regurgitation. These
auscultatory signs are best appreciated with the patient in the left lateral
decubitus position .
 Examination of the fundi may reveal an evidence of hypertension as increased
light reflex and arteriovenous nicking . Aortic stenosis, aortic
regurgitation,pulmonary hypertension and hypertrophic cardiomyopathy must
be excluded, since these disorders may cause angina in the absence of coronary
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atherosclerosis. Examination during an anginal attack is useful, since ischemia
can cause transient left ventricular failure with the appearance of a third and/or
fourth heart sound, a dyskinetic cardiac apex, mitral regurgitation, and even
pulmonary edema. Tenderness of the chest wall, localization of the discomfort
with a single fingertip on the chest, or reproduction of the pain with palpation
of the chest makes it unlikely that the pain is caused by myocardial ischemia.
2. NON INVASIVE TESTING :
a. Biochemical test :
Since the risk factors for stable IHD are hypercholesterolemia and other
dyslipidemias , carbohydrate intolerance, and insulin resistance. All patients with
established or suspected CAD  can do the biochemical evaluation of total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL)
cholesterol, triglyceride, serum creatinine (estimated glomerular filtration), and fasting
blood glucose levels. Measurement of lipoprotein (a) , lipoprotein-associated
phospholipase A2 (Lp-PLls A2) and homocysteine levels will provide information
about  the future events of ischemic heart disease.
Understanding  the pathobiology of stable IHD have generated interest in
inflammatory biomarkers as noninvasive indicators of underlying atherosclerosis and
cardiovascular risk. The serum concentration of high-sensitivity C-reactive protein
has shown a relationship to the risk of incident cardiovascular events. Other
biomarkers of inflammation, such as myeloperoxidase, growth factors, and
metalloproteinases are  markers of underlying atherosclerosis remain under study.34
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By assessing the blood levels of cardiac troponin as markers of necrosis are
typically used to differentiate patients with acute MI from those with stable IHD..
Novel biomarkers of myocardial ischemia are the plasma concentration of brain
natriuretic peptide (BNP) ,N-terminal pro-BNP are under study .Circulating
biomarkers of myocyte injury have now been detected in patients with clinically stable
IHD and shown to have a graded relationship with the subsequent risk of
cardiovascular mortality and heart failure.
b. Resting Electrocardiography:
The most common electrocardiographic abnormalities in patients with chronic
IHD  are nonspecific ST-T wave changes, with or without abnormal Q waves. In
addition to myocardial ischemia, other conditions that can produce ST-T wave
abnormalities include LV hypertrophy and dilation, electrolyte abnormalities,
neurogenic effects, and antiarrhythmic drugs . Various conduction disturbances, most
frequently left bundle branch block and left anterior fascicular block, may occur in
patients with stable IHD and are often associated with impairment of LV function and
reflect multivessel CAD and previous myocardial damage. LV hypertrophy on the
ECG is an indicator of worse prognosis in patients with chronic stable angina.35
c. Noninvasive Stress Testing:
Noninvasive stress testing  can provide useful information to establish the
diagnosis and estimate the prognosis in patients with chronic stable angina.
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d. Exercise Electrocardiography:
The exercise ECG is particularly helpful for patients with  angina pectoris who
are considered to have a moderate probability of CAD provided they are capable of
achieving an adequate workload and in whom the resting ECG is normal.
Interpretation of the exercise test should include consideration of the exercise capacity
, clinical, hemodynamic, and electrocardiographic responses. Antianginal
pharmacologic therapy reduces the sensitivity of exercise testing as a screening tool. .
Two or 3 days of interruption is required for patients receiving long-acting beta
blockers.For long-acting nitrates, calcium antagonists, and short-acting beta blockers,
discontinuing use of the medications the day before testing is required. Therefore, if
the purpose of the exercise test is to diagnose ischemia, it should be performed in the
absence of antianginal medications.
e. Stress Echocardiography
Stress echocardiography  may be performed using exercise or pharmacologic
stress and allows for the detection of regional ischemia by identifying areas of wall
motion disorders. Two-dimensional echocardiography is useful for the evaluation of
patients with chronic CAD because it can assess global and regional LV function
under basal conditions and during ischemia, as well as detect LV hypertrophy and
associated valve disease. Pharmacologic stress, such as with injection dobutamine,
should be used for patients unable to exercise, those unable to achieve adequate heart
rates with exercise, and those in whom the quality of the echocardiographic images
during or immediately after exercise is poor.
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f. Stress Myocardial Perfusion Imaging:
Stress testing should be performed only if there is no evidence of CAD in
resting ECG .Perfusion imaging is also valuable for detecting myocardial viability in
patients with regional or global LV dysfunction, with or without Q waves, and
provides important information in regard to prognosis .Exercise perfusion imaging
with simultaneous electrocardiographic testing is superior to exercise
electrocardiography alone in detecting CAD, identifying multivessel CAD, localizing
diseased vessels, and determining the magnitude of ischemic and infarcted
myocardium. Exercise single-photon emission computed tomography (SPECT)
provides  higher sensitivity and specificity  compared with exercise
electrocardiography alone.
g. Chest Roentgenography :
The chest roentgenogram  is usually within normal limits in patients with stable
IHD. If cardiomegaly is present, it is indicative of severe CAD with previous MI,
preexisting hypertension, or an associated nonischemic condition, such as concomitant
valvular heart disease, pericardial effusion, or cardiomyopathy.
h. Computed Tomography :
Cardiac multidetector CT(MDCT) has made substantial advances as a
noninvasive approach to imaging atherosclerosis . MDCT can also provide an
angiogram of the coronary arterial tree. CT angiography may be reasonable for
symptomatic patients at intermediate risk for coronary disease after initial evaluation
in  those with indeterminate results of stress testing. In addition to providing a highly
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sensitive method for detecting coronary calcification which is diagnostic of coronary
atherosclerosis.
i. Cardiac Magnetic Resonance Imaging :
Cardiac magnetic resonance imaging( CMR) is evolving as a versatile
noninvasive cardiac imaging modality that has multiple applications for patients with
IHD.It is established as a valuable clinical tool for imaging the aorta and cerebral and
peripheral arterial vasculature. CMR is continuing to develop as a single approach to
assessment of cardiac function, structure, blood flow, and viability without exposing
the patient to ionizing radiation .it is useful to characterize congenital coronary
anomalies and to detect stenoses in the proximal and middle segments of major
epicardial vessels or surgical bypass grafts.
3. INVASIVE TESTING :
Catheterization and Coronary Arteriography:
The clinical examination and noninvasive techniques described are extremely
valuable for establishing the diagnosis of CAD. Currently definitive diagnosis of
CAD and precise assessment of its anatomic severity still require cardiac
catheterization and coronary arteriography. Advanced invasive imaging techniques
such as intravascular ultrasonography (IVUS) provide a cross-sectional view of the
coronary artery and have substantially enhanced the detection and quantification of
coronary atherosclerosis, as well as the potential to characterize the vulnerability of
coronary atheroma. Angiography techniques provide information about reduced size
of the coronary collaterals ,presence of myocardial bridging , defective LV wall
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motion ,reduced coronary blood flow and abnormal myocardial  metabolism
suggestive of chronic IHD . The most serious limitation to the routine use of coronary
angiography for prognosis in patients with stable IHD is its inability to identify which
coronary lesions can be considered to be at high risk, or vulnerable, for future events,
such as MI or sudden death.36
X. MEDICAL MANAGEMENT OF IHD :
Comprehensive management of stable IHD has five aspects: 37
(1) identification and treatment of associated diseases that can precipitate angina and
ischemia;
(2) reduction of coronary risk factors;
(3) application of pharmacologic and nonpharmacologic interventions for secondary
prevention, with particular attention to adjustments in lifestyle;
(4) pharmacologic management of angina; and
1)TREATMENT OF ASSOCIATED DISEASES:
In patients with CAD or tachyarrhythmias can increase myocardial O2 need
with an increase in the frequency and severity of angina. Identification and treatment
of these conditions are essential to the management of stable IHD. Several common
medical conditions include anemia, marked weight gain, occult thyrotoxicosis, fever,
infections and tachycardia. Cocaine, which can cause acute coronary spasm and MI .
Therefore these conditions should be diagnosed early and managed accordingly.
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2)REDUCTION OF CORONARY RISK FACTORS:
a) Cigarette Smoking :
 Smoking remains one of the most powerful risk factors for the development of
CAD in all age groups. Cigarette smokers have a higher 5-year risk of sudden
death, MI, and all-cause mortality than those who have stopped smoking in
patients with angiographically documented CAD38. Moreover, smoking
cessation lessens the risk of adverse coronary events in patients with
established CAD. Cigarette smoking may be responsible for aggravating angina
in addition to progression of atherosclerosis, it may increase myocardial O2
demand and reduce coronary blood flow by an alpha-adrenergically mediated
increase in coronary artery tone and thereby cause acute ischemia. . It causes
vasoconstriction via activation of the sympathetic nervous system and platelet
activation/aggregation with a consequent increase in thromboxane A2
biosynthesis Moreover, passive exposure to smoke has adverse cardiovascular
effects that are almost as great as those of active smoking. Smoking cessation is
one of the most effective and cost-effective approaches to the prevention of
disease progression in native vessels and bypass grafts.
 Nicotine(cigaretee) is a potent drug of dependence. Withdrawal can lead to an
“abstinence syndrome” consisting of craving, irritability and sometimes
physical features (e.g. alimentary disturbances). A treatment programme should
include medical , psychological and social support.
 Bupropion appears to reduce the desire to smoke and used as an adjunct to
motivational support in smoking cessation. It is contraindicated in patients with
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a history of seizures or of eating disorders, or who are experiencing acute
alcohol or benzodiazepine withdrawal.
 Varenicline, a selective nicotinic receptor partial agonist, is an oral adjunct to
smoking cessation. It is started 1–2 weeks before stopping smoking. It is
contraindicated in pregnancy. Side effects include gastro-intestinal
disturbances, headache, dizziness and sleep disorders.
 Nicotine skin patches or nicotine gum as part of a smoking cessation
programme significantly increases success rates.39
b) Management of Dyslipidemia:
Most patients with dyslipidaemia have a combination of genetic and dietary
factors. Secondary forms of dyslipidaemia are diabetes,hypothyroid,primary biliar
cirrhosis and chronic kidney disease. Reducing the total plasma cholesterol
concentration reduces the risk of coronary heart disease and can cause regression of
atheroma.. In people without clinical evidence of atheromatous disease, the decision
as to whether to initiate drug treatment at any given level of serum lipids should be
informed by the risk of coronary events.
Lipid-lowering with statins (taken once daily at night) which is effective and
has been shown to reduce  in serum LDL cholesterol levels  . In addition it would
reduce circulating levels of hsCRP, decrease thrombogenicity, and favorably alter the
collagen and inflammatory components of arterial atheroma  and suggest
antiatherothrombotic properties of statins. These properties may contribute to
reduction in inducible myocardial ischemia, improvement in blood flow, and the
reduction in coronary events in patients treated with statins. Also, in a large
randomized, placebo-controlled trial in individuals with average LDL levels and no
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known atherosclerosis but an increased risk of atherothrombosis identified with
elevated hsCRP, statin therapy reduced the risk of first major cardiovascular events.
Mild and infrequent side effects of statins  include nausea, constipation,
diarrhoea, flatulence, fatigue, insomnia and rash. More serious adverse events are
rhabdomyolysis, hepatitis and angioedema. Liver function tests should be performed
before starting treatment and at intervals. HMG CoA reductase inhibitors should be
avoided in alcoholics and patients with active liver disease, and are contraindicated
during pregnancy. Statins are well absorbed, extracted by the liver  and are subject to
extensive presystemic metabolism by CYP3A4 or CYP2D6. The risk of
rhabdomyolysis is increased by concurrent use of a fibrate or inhibitors of statin
metabolism, e.g. azoles .40
c) Management of Diabetes Mellitus :
Patients with diabetes mellitus are at significantly higher risk of atherosclerotic
vascular disease. A favorable impact of control of glycemia on microvascular
complications of diabetes is well established. But the macrovascular complications on
of diabetes on control of glycemia is not well established. In an analysis of a
secondary endpoint of the PROACTIVE Trial, treatment of patients with type 2
diabetes with the oral hypoglycemic agent pioglitazone reduced the risk of death,
nonfatal MI, or stroke.41According to  the Diabetes Control and Complications Trial ,
during a mean follow-up of 17 years in patients with type 1 diabetes assigned to
intensive glycemic therapy were at lower risk of cardiovascular
complications.Several large trials evaluating the effects of oral hypoglycemic agents
on cardiovascular outcomes are ongoing. Management of hypercholesterolemia and
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hypertension are particularly important in patients with type 2 diabetes.
d) Inflammation :
Atherothrombosis has been recognized as an inflammatory disease.Markers of
systemic inflammation, of which hsCRP is seen in patients with established vascular
disease who are at higher risk for future ischemic events. Therefore, inflammation
has been identified as a potential target for therapeutic intervention in patients with
IHD. For example, in a number of studies, treatment with statins has lowered the
serum concentration of hsCRP. In addition, lower levels of hsCRP achieved with
statin therapy in patients 1 month after an ACS are associated with better long-term
prognosis . Aspirin, ACE inhibitors, thiazolidinediones, thienopyridines, and fibric
acid derivatives are among those agents that have been shown to exert anti-
inflammatory or immunoregulatory actions .Other established preventive
interventions, as well as novel therapeutic strategies, may also have anti-
inflammatory effects that could target inflammation.
e) Obesity :
Obesity is an independent contributor to the risk for IHD and is associated with
other risk factors, including hypertension, dyslipidemia, and abnormal glucose
metabolism. Weight loss can improve or prevent many of the cardiovascular
consequences of obesity.
33
3)ADDITIONAL DISEASE-MODIFYING PHARMACOTHERAPY FOR
SECONDARY PREVENTION :
Antiplatelet drugs:
 Aspirin:
Aspirin blocks production of TxA2 by acetylating a serine residue near the active
site of platelet cyclooxygenase-1 (COX-1), the enzyme that produces the cyclic
endoperoxide precursor of TxA2.42 According to antithrombotic trials low dose aspirin
reduce the risk of MI by 87% during 5 yrs follow up. Low dose  aspirin 75 to 162 mg
daily is preferred for secondary prevention in the absence of recent intracoronary
stenting.43
 Clopidogrel :
Clopidogrel, a thienopyridine derivative  may be substituted for aspirin in patients
with aspirin hypersensitivity or those who cannot tolerate aspirin. Clopidogrel is a
prodrug with a slow onset of action .Clopidogrel is an irreversible inhibitor of
platelet P2Y12 receptors but is more potent and has a more favorable toxicity profile
than ticlopidine, with thrombocytopenia and leukopenia occurring only rarely .The
usual dose is 75 mg/day with or without an initial loading dose of 300 or 600 mg. The
drug is somewhat better than aspirin in the secondary prevention of stroke, and the
combination of clopidogrel plus aspirin is superior to aspirin alone for prevention of
recurrent ischemia in patients with unstable angina. The superiority of the
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combination suggests that the actions of the two drugs are synergistic, as might be
expected from their distinct mechanisms of action. The FDA-approved indications for
clopidogrel are to reduce the rate of stroke, myocardial infarction, and death in
patients with recent myocardial infarction or stroke, established peripheral arterial
disease, or acute coronary syndrome.23 Ongoing studies are testing the hypothesis that
more potent antiplatelet therapy than aspirin alone is useful for patients with stable
IHD.44
i. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor
Blockers:
Although inhibitors of the renin-angiotensin-aldosterone system are not
indicated for the treatment of angina, these drugs appear to have important benefits in
reducing the risk of future ischemic events in some patients with cardiovascular
disease.24 The potentially beneficial effects of ACE inhibitors include reduction in
LV hypertrophy, vascular hypertrophy, progression of atherosclerosis, plaque rupture,
and thrombosis, in addition to a potentially favorable influence on myocardial O2
supply and demand relationships, cardiac hemodynamics, sympathetic activity, and
coronary endothelial vasomotor function. In addition, in vitro experiments have
shown that angiotensin II induces inflammatory changes in human vascular smooth
muscle cells, and treatment with ACE inhibitors can reduce signs of inflammation in
animal models of atherosclerosis. ACE inhibitors may be considered for optional use
in all other patients with stable IHD with normal LV ejection fraction and
cardiovascular risk factors that are well controlled in whom revascularization has
been performed.
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ii. Antioxidants :
Oxidized LDL particles are strongly linked to the pathophysiology of
atherogenesis. Descriptive, prospective cohort, and case-control studies have
suggested that a high dietary intake of antioxidant vitamins (A, C, and beta-
carotene) and flavonoids (polyphenolic antioxidants), naturally present in
vegetables, fruits, tea, and wine is associated with a decrease in CAD events . Thus,
based on current evidence, there is no basis for recommending that individuals take
supplemental folate, vitamin E, vitamin C, or beta-carotene for the purpose of
treating CAD. Additional investigation of other approaches to antioxidant therapy is
ongoing.
iii. Counseling and Changes in Lifestyle:
 Depression and angina :
Depressive symptoms are associated with higher levels of circulating biomarkers of
inflammation. In conjunction with counseling, treatment with a selective serotonin
reuptake inhibitor appears to be safe and effective for managing depression in
patients with IHD. Moreover, psychosocial stress at work, home, or both is
associated with an increased risk of MI and may be a target for preventive
interventions.Depressive symptoms are strongly associated with health status as
reported by the patient, including the burden of symptoms and overall quality of life,
independently of LV function and the presence of provokable ischemia. In addition,
the association between depressive symptoms and IHD may reflect a causal
relationship between the former and atherothrombosis.
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 Physical activity and angina :
An important aspect of the physician's role is to counsel the patients with respect to
dietary habits, goals for physical activity, the types of work they can do, and their
leisure activities. Certain changes in lifestyle may be helpful, such as modifying
strenuous activities if they constantly and repeatedly produce angina. However,
isometric activities such as weightlifting expose the individual to the detrimental
effects  on the O2 demand and supply relationship, and these activities should also
be avoided whenever possible. Although it is desirable to minimize the number of
bouts of angina, an occasional episode is not to be feared. Patients learn their usual
threshold by trial and error. Eliminating or reducing the factors that precipitate
anginal episodes is of obvious importace. Patients should avoid sudden bursts of
activity, particularly after long periods of rest, after meals, and in cold weather.
Both chronic and unstable angina exhibit a circadian rhythm characterized by a
lower angina threshold shortly after arising. Therefore, morning activities such as
showering, shaving, and dressing should be done at a slower pace and, if necessary,
with the use of prophylactic nitroglycerin. The stress of sexual intercourse induces a
heart rate of approximately 120 beats/min. With proper precautions (i.e.,
commencing more than 2 hours postprandially and taking an additional dose of a
short-acting beta blocker 1 hour before and nitroglycerin 15 minutes before), most
patients with stable angina are able to continue satisfactory sexual activity .
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4)PHARMACOLOGICAL  MANAGEMENT OF IHD:
I. NITRATES:
History of Nitrates:
Nitroglycerin was first synthesized in 1846 by Sobrero, who observed that a
small quantity placed on the tongue elicited a severe headache. The explosive
properties of nitroglycerin also were soon noted by Alfred Nobel.In 1857, T. Lauder
Brunton of Edinburgh administered amyl nitrite, a known vasodepressor, by
inhalation and noted that anginal pain was relieved within 30- 60 seconds.45 The
action of amyl nitrite was transitory, however, and the dosage was difficult to adjust.
Subsequently, William Murrell established that sublingual nitroglycerin for relief of
the acute anginal attack and as a prophylactic agent to be taken prior to exertion. In
1998 ,the importance of NO as a signaling molecule in the cardiovascular system
and was recognized by the pharmacologists Robert Furchgott, Louis Ignarro, and
Ferid Murad , awarding the Nobel Prize in medicine/physiology.46
Source and Synthesis :
The endogenous synthesis of NO in humans is catalyzed by a family of NO
synthases that oxidize the amino acid L-arginine to form NO, plus L-citrulline as a
co-product. There are three distinct mammalian NO synthase isoforms termed as
nNOS, eNOS, and iNOS . They are involved in processes as diverse as
neurotransmission, vasomotion, and immunomodulation.
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Mechanism of Action:
The action of nitrate group of agents is to relax vascular smooth muscle. The
vasodilator effects of nitrates are predominant in the venous circulation. The
venodilator effect reduces ventricular preload, which in turn reduces myocardial
wall tension and O2 requirements. The action of nitrates in reducing preload and
afterload makes them useful in the treatment of heart failure as well as angina. By
reducing the cardiac mechanical activity, volume, and O2 consumption, nitrates
increase exercise capacity in patients with IHD, thereby allowing a greater total
body workload to be achieved before the angina threshold is reached. Thus, in
patients with stable angina, nitrates improve exercise tolerance and time to ST-
segment depression during treadmill exercise tests. When used in combination with
calcium channel blockers and/or beta blockers, the antianginal effects appear
greater.
Effects on the Coronary Circulation:
Nitroglycerin causes dilation of epicardial arteries more than endocardial
arteries . These stenoses are often eccentric lesions, and nitroglycerin causes
relaxation of the smooth muscle in the wall of the coronary artery that is not
encompassed by plaque. Even a small increase in a narrowed arterial lumen can
produce a significant reduction in resistance to blood flow across obstructed regions.
Nitrates may also exert a beneficial effect in patients with impaired coronary flow
reserve by alleviating the vasoconstriction caused by endothelial dysfunction.
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Redistribution of Blood Flow:
Nitroglycerin causes redistribution of blood flow from normally perfused to
ischemic areas, particularly in the subendocardium. This redistribution may be
mediated in part by an increase in collateral blood flow and in part by lowering of
LV diastolic pressure, thereby reducing subendocardial compression.
Nitroglycerin appears to reduce coronary vascular resistance preferentially in
viable myocardium with ischemia, as detected by SPECT imaging. In patients
with chronic stable angina responsive to nitroglycerin, topical nitroglycerin under
resting conditions alters myocardial perfusion by preferentially increasing flow to
areas of reduced perfusion, with little or no change in global myocardial
perfusion.
Cellular Mechanism of Action:
Nitrates have the ability to cause vasodilation, regardless of whether the
endothelium is intact. After entering the vascular smooth muscle cell, nitrates are
converted to reactive NO or S-nitrosothiols, which activate intracellular guanylate
cyclase to produce cGMP, which in turn triggers smooth muscle relaxation and
antiplatelet aggregator effects .Evidence now indicates that the biotransformation
of nitroglycerin occurs via mitochondrial aldehyde dehydrogenase and inhibition
of this enzyme may contribute to the development of tolerance. Although the
aggregate evidence supports the release of NO as the major cellular mechanism
of action of oral nitrates, experimental data have raised challenges to this
conclusion. In particular, the arterial vasodilatory effects of nitroglycerin in vitro
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depend at least in part on endothelial calcium-activated potassium channels.
FIGURE 4
MECHANISM OF ACTION OF NITRATE
Types of Preparations and Routes of Administration:
Nitroglycerin administered sublingually remains the drug of choice for the treatment
of acute angina episodes and for the prevention of angina. Because sublingual
administration avoids first-pass hepatic metabolism. The half-life of nitroglycerin
itself is brief and it is readily converted to two inactive metabolites both of which
are excreted in the urine. Within 30 to 60 minutes, hepatic breakdown has abolished
the hemodynamic and clinical effects. The usual sublingual dose is 0.3 to 0.6 mg,
and most patients respond within 5 minutes. If symptoms are not relieved by a single
dose, additional doses of 0.3 mg may be taken at 5-minute intervals, but no more
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than 1.2 mg should be used within a 15-minute period. The development of
tolerance is rarely a problem with intermittent use. Sublingual nitroglycerin is
especially useful when taken prophylactically shortly before undertaking physical
activities that are likely to cause angina. When used for this purpose, it may prevent
angina for up to 40 minutes. 47
Preparations:
 Nitroglycerin Tablets:
Nitroglycerin tablets tend to lose their potency, especially if exposed to light, and
should thus be kept in dark containers. An oral nitroglycerin spray that dispenses
metered, aerosolized doses of 0.4 mg may be better absorbed than the sublingual
form by patients with dry mucosal membranes. Other nitrate preparations are
available in sublingual, buccal, oral, spray, and ointment forms .
 Isosorbide Dinitrate:
This drug is an effective antianginal agent but has low bioavailability after oral
administration. It has two metabolites, one with potent vasodilator action, which are
cleared less rapidly than the parent drug and excreted unchanged in the urine. It is
available in tablets for sublingual use, in chewable form, in tablets for oral use, and
in sustained-release capsules.
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 Isosorbide 5-Mononitrate:
This active metabolite of the dinitrate is completely bioavailable with oral
administration because it does not undergo first-pass hepatic metabolism; it is
efficacious in the treatment of chronic stable angina.  A single 20-mg tablet exhibits
activity 8 hours after administration. The sustained-release preparation of isosorbide
5-mononitrate may be given once daily in a dosage of 30 to 240 mg.
 Topical Nitroglycerin:
1.Ointment : Nitroglycerin ointment (15 mg/inch) is efficacious when applied in
strips of 0.5 to 2.0 inches. This form of the drug is effective for 4 to 6 hours, it is
particularly useful for patients with severe angina or unstable angina who are
confined to bed and chair. Skin permeability increases with increased hydration, and
absorption is also enhanced if the paste is covered with plastic, with the edges taped
to the skin.
2.Transdermal Patches. Application of silicone gel or polymer matrix impregnated
with nitroglycerin results in absorption for 24 to 48 hours at a rate determined by
various methods of preparation of the patch, including a semipermeable membrane
placed between the drug reservoir and the skin. The release rate of the patches varies
from 0.1 to 0.8 mg/hr.
Adverse Drug Reactions:
Adverse reactions are common and include headache, flushing, and
hypotension. The last is rarely severe but, in some patients with volume depletion
and in an upright posture, nitrate-induced hypotension is accompanied by a
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paradoxical bradycardia, consistent with a vasovagal or vasodepressor response.
This reaction is more common in older patients, who are less able to tolerate
hypovolemia. Methemoglobinemia is a rare complication of very large doses of
nitrates. Commonly used doses of nitrates cause small elevations of methemoglobin
levels.
Nitrate Tolerance:
A major problem with the use of nitrates is the development of nitrate
tolerance, which has been demonstrated with all forms of nitrate administration.
Although nitrate tolerance is rapid in onset, renewed responsiveness is easily
established after a short nitrate-free interval. The problem of tolerance applies to all
nitrate preparations ,it is particularly important in patients with chronic angina, as
opposed to those receiving short-acting courses of nitrates . Despite continuous
administration of nitroglycerin for 48 hours nitrate tolerance appears to be limited to
the capacitance and resistance vessels and has not been noted in the large
conductance vessels, including the epicardial coronary arteries and radial arteries.
Mechanisms of nitrate tolerance :
Several mechanisms of nitrate tolerance have been proposed. Evidence has
supported the hypothesis that increased generation of vascular superoxide anion
(?O2−) is the central process. There are a number of consequences of increased
superoxide anion formation; these include plausible links to many of the proposed
mechanisms of nitrate tolerance:
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(1) plasma volume expansion and neurohormonal activation;
(2) impaired biotransformation of nitrates to NO; and
(3) decreased end-organ responsiveness to NO.48
Management of nitrate tolerance:
The primary strategy to manage nitrate tolerance is to prevent it by providing a
nitrate-free interval. The optimal interval is not known, but with patches or ointment
of nitroglycerin or preparations of isosorbide dinitrate or isosorbide 5-mononitrate, a
12-hour off-period is recommended.
Nitrate Withdrawal:
A common form of nitrate withdrawal (rebound) is observed in patients whose
angina is intensified after discontinuation of large doses of long-acting nitrates. In
this situation, patients may also have heightened sensitivity to constrictor stimuli.
The potential for rebound can be modified by adjusting the dose and timing of
administration in addition to the use of other antianginal drugs.
Interaction with PDE5 Inhibitors:
Nitrate therapy is an absolute contraindication to the use of PDE5 inhibitors.The
combination of nitrates and PDE5 inhibitors, such as sildenafil, may cause serious,
prolonged, and potentially life-threatening hypotension. 49
II. Beta-Adrenergic Blocking Agents:
Mechanism of action :
Beta-adrenergic blocking drugs constitute a cornerstone of therapy for angina.
The beneficial actions of these drugs depend on their ability to cause competitive
inhibition of the effects of neuronally released and circulating catecholamines on
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beta adrenoceptors. In addition to their anti-ischemic properties, beta blockers are
effective antihypertensives  and antiarrhythmics . They have also been shown to
reduce mortality and reinfarction in patients after MI and to reduce mortality in
patients with heart failure . This combination of actions makes them extremely
useful in the management of stable IHD.
FIGURE 5
Dosage:
For optimal results, the dosage of a beta blocker should be carefully
adjusted.The usual effective dosage of atenolol  is 50 to 100 mg daily up to a
maximum of 200 mg daily. In the case of metoprolol, an extended-release
formulation, which may be started at a dose of 100 mg once daily.Efficacy is
determined by the effect on heart rate and symptoms and, the effect on exercise
performance can be evaluated by treadmill exercise testing. The resting heart rate
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should be reduced to between 50 and 60 beats/min, and an increase of less than 20
beats/min should occur with modest exercise (e.g., climbing one flight of stairs).
Therapy with beta blockers needs to be individualized and requires repeated clinical
evaluation during the initial period of drug administration.
Adverse Effects and Contraindications:
Most of the adverse effects of beta blockers occur as a consequence of the
known properties of these drugs and include cardiac effects (e.g., severe sinus
bradycardia, sinus arrest, AV block, reduced LV contractility), bronchoconstriction,
fatigue, mental depression, nightmares, gastrointestinal upset, sexual dysfunction,
intensification of insulin-induced hypoglycemia, and cutaneous reactions . Lethargy,
weakness, and fatigue may be caused by reduced cardiac output or may arise from a
direct effect on the central nervous system. Bronchoconstriction results from
blockade of beta2 receptors in the tracheobronchial tree. As a consequence, asthma
and chronic obstructive lung disease may be considered as relative contraindications
to beta blockers, even to beta1-selective agents.
III. CALCIUM CHANNEL BLOCKERS:
The critical role of calcium ions in the normal contraction of cardiac and
vascular smooth muscle . The calcium antagonists  are a heterogeneous group of
compounds that inhibit calcium ion movement through slow channels in cardiac and
smooth muscle membranes by noncompetitive blockade of voltage-sensitive L-type
calcium channels. The two predominant effects of calcium antagonists result from
blocking the entry of calcium ions and slowing recovery of the channel.
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The three major classes of calcium antagonists are the dihydropyridines
(nifedipine is the prototype), the phenylalkylamines (verapamil is the prototype),
and the modified benzothiazepines (diltiazem is the prototype).
Mechanism of Action:
The efficacy of calcium antagonists in patients with angina pectoris is related
to the reduction in myocardial O2 demand and the increase in O2 supply. The latter
effect is particularly important in patients with conditions in which a prominent
vasospastic or vasoconstrictor component may be present, such as Prinzmetal
(variant) angina , variable-threshold angina, and angina related to impaired
vasodilator reserve of small coronary arteries. Calcium antagonists may be effective
on their own or in combination with beta-adrenergic blockers and nitrates in patients
with chronic stable angina. Several calcium antagonists are effective for the
treatment of angina pectoris. Each relaxes vascular smooth muscle in the systemic
arterial and coronary arterial beds. In addition, blockade of the entry of calcium into
myocytes results in a negative inotropic effect, which is counteracted to some extent
by peripheral vascular dilation and by activation of the sympathetic nervous system
in response to drug-induced hypotension.However, the negative inotropic effect
must be taken into consideration in patients with significant LV dysfunction.
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Antiatherogenic Action:
Hyperlipidemia-induced changes in the permeability of smooth muscle cells to
calcium may play a role in atherogenesis.More lipophilic second-generation agents
such as amlodipine, have demonstrated improved endothelial function, inhibition of
smooth muscle cell proliferation, migration, and ameliorated unfavorable membrane
alterations.
Drug interactions :
CCBs inhibit the CYPA4 enzyme in the liver and, therefore, may raise levels of
statinsand many other drugs, which may be overlooked. Cimetidine and grapefruit
juice may raise the effective level of CCBs. Since magnesium is a calcium
antagonist, magnesium supplements may enhance the actions of CCBs, particularly
nifedipine.
Adverse Effects:
Common side effects of headache, dizziness, flushing, ankle edema are due to
vasodilation. Interaction with other negative chronotropic or inotropic agents to
produce bradycardia, heart block, or HF has been reported. CCBs may also suppress
lower esophageal sphincter contraction and worsen symptoms of gastroesophageal
reflux disease.
IV. NEWER, NONTRADITIONAL ANTI-ISCHEMIC AGENTS:
a. NICORANDIL:
Nicorandil is structurally a nicotinamide derivative with a nitrate moiety and
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a dual mechanism of action. First, it increases potassium ion conductance by
opening adenosine triphosphate (ATP)-sensitive potassium channels, in turn
activating the enzyme guanylate cyclase. Second, nicorandil shares the smooth
muscle-relaxing property of nitrates to vasodilate, lowering preload through
venodilation. The drug also reduces afterload and promotes expression of
endothelial NO synthase.Use is associated with improved myocardial function
during ischemia-reperfusion,protection of myocardium during ischemia, shortened
action potential duration, and prevention of intracellular calcium toxicity, of
importance in modulating ischemic cell damage and death. 50 In addition to these
effects, nicorandil may have cardioprotective actions mediated through the
activation of potassium channels. Nicorandil has been associated with ulcerations of
the gastrointestinal tract.
b. TRIMETAZIDINE:
Trimetazidine, a member of the class of “3-ketoacyl coenzyme A thiolase (3-
KAT) inhibitors,” is a metabolic modulator that improves myocardial energetics at
several levels, partially inhibiting β-oxidation of fats by decreasing activity of
mitochondrial enzyme 3-KAT.The drug raises myocardial glucose utilization,
prevents a decrease in ATP and phosphocreatine levels in response to hypoxia or
ischemia, preserves ionic pump function, minimizes free radical production, and
protects against intracellular calcium overload and acidosis. It raises coronary flow
reserve, lowers frequency of anginal episodes, improves exercise performance, and
spares the use of nitrates without changes in heart rate, negative inotropic, or
vasodilator actions.51
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c. RANOLAZINE:
Ranolazine is a piperazine derivative that inhibits the late sodium channels, not
only lowering total inward sodium flux but also the subsequent intracellular calcium
overload.At therapeutic concentrations, fast inward sodium current is unchanged,
and reduction of late inward sodium current is confined to ischemic or failing
myocytes. By blunting the amount of excess sodium entering the cell, the total
intracellular sodium concentration is restricted, thereby limiting the ischemia-
associated calcium overload, the lethal component of events.The drug interrupts the
positive feedback loop that perpetuates myocardial ischemia, sodium influx, loss of
potassium, voltage gradient perturbations, and myocardial dysfunction. By
preventing intracellular sodium overload, calcium accumulation is prevented,
diastolic muscle relaxation is normalized, and myocardial oxygen balance and
myocardial blood perfusion are preserved. Improvement in the dual changes in
intracellular sodium and calcium promotes electrical stability, minimizing the pro
arrhythmogenic effects of ischemia. Ranolazine also reduces the late inward calcium
current, the inward Na+/Ca2+ exchange current, and the outward repolarizing,
delayed rectifier potassium current. Ion channel changes induced by ranolazine
resemble those of amiodarone.
The half-life of the sustained-release formulation of ranolazine is
approximately 7 hours. A steady state is generally achieved within 3 days of dosing
twice daily. Ranolazine is metabolized primarily through the cytochrome P-450
(CYP3A4) pathway and thus the plasma concentration is increased if administered
in combination with moderate (e.g., diltiazem) or strong (e.g., ketoconazole and
macrolide antibiotic) inhibitors of this system. Verapamil increases the absorption of
51
ranolazine by inhibition of P-glycoprotein. Plasma concentrations of simvastatin are
increased approximately twofold after administration of ranolazine.52
d. FASUDIL :
Rho kinase, or “ROCK”, is an important intracellular enzyme which
phosphorylates proteins to affect a number of cellular functions, among them
phosphorylation of myosin, resulting in smooth muscle contraction and
vasoconstriction. Fasudil is a rho-kinase inhibitor that has been used to prevent
vasospasm, especially in the pulmonary and cerebral arterial beds, in addition to
inhibiting production of vascular endothelial growth factor. 53The  drug is effective
and safe in patients with stable angina who are already being treated with traditional
agents.
e. IVABRADINE:
Ivabradine is a new anti-ischemic antianginal agent which acts purely through
heart rate reduction without affecting other cardiac functions. It is useful in
maintaining myocardial contractility, atrioventricular conduction and ventricular
repolarisation. Also there is no indirect alpha-stimulating activity which is
responsible for the vasoconstriction seen with beta blockers. Ivabradine is now
available as monotherapy for symptomatic treatment of patients with chronic stable
angina and normal sinus rhythm but who are intolerant to beta blockers or have a
contraindication to their use54.
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Mechanism of action:
a)Selective sinus node If inhibition:
Heart rate is controlled by the sinoatrial node located in the right atrium. This is
where the action potential is created and is conducted to the ventricles triggering
ventricular contraction.
The sinoatrial myocytes are the heart’s pacemaker cells. They generate an action
potential by electrical depolarisation, which spreads from the sinus node through the
cardiac conducting tissue in a controlled wave to coordinate cardiac contraction.
This pacemaker activity controls heart rate and depends on interaction between
several ionic currents involved in diastolic depolarisation. The f-channel (funny due
to its unusual properties) allows sodium ions to move inwards and potassium ions to
move outwards across the cell membrane through a hyperpolarisation activated,
cyclic nucleotide-gated (HCN) channel so generating the If current. This is the
major determinant of the diastolic depolarization slope of the sinus node. The
channels are open during the diastolic depolarisation phase and closed at the peak of
the action potential. Therefore, targeting the f-channel can directly affect the
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frequency of the action potential.55 At therapeutic concentrations ivabradine had no
significant effect on other cardiac ionic currents or cardiac action potential shape
and therefore its action was found to be selective and specific .Ivabradine
specifically binds to the f-channel on the intracellular side of sinoatrial pacemaker
cell membrane and blocks the entry of sodium ions into the cell. This action causes
selective inhibition of the If current, in a dose dependent manner, which plateaus at
higher concentrations. Blocking the If current causes a reduction in the slow
diastolic depolarisation slope, without affecting maximal diastolic potential or
threshold activation potential, which exhibits a use-dependent effect on heart rate.
Figure 7
Pharmacodynamic If channel interaction and the effect on the sinoatrial action
potential56
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b)Pure heart rate reduction:
Heart rate reduction is a major determinant in maintaining myocardial oxygen
supply. This is the common mechanism of action for beta-blockers and ivabradine in
anti-anginal therapy, as heart rate reduction reduces exercise-induced ischemia by
increasing diastolic perfusion time57. However these are distinct actions and other
anti-anginal agents (ranolazine, trimetazidine) can reduce exercise-induced ischemia
without having any effect on diastolic perfusion time. During exercise, increase in
left ventricular (LV) filling rate depends on the ability of the left ventricle to relax
and beta blockers alter this relaxation process by their intrinsic negative inotropic
properties.58Ivabradine, unlike atenolol, reduced exercise-induced acceleration in
heart rate without simultaneously exerting intrinsic depressant effects on of the rate
of LV relaxation. Ivabradine was found to reduce heart rate both at rest and during
exercise , without any inotropic effects or effect on left ventricular systolic function
or coronary vasomotor activity. Ivabradine reduced heart rate in a dose-dependent
manner when administered intravenously and orally.59
c)Improving the left ventricular function:
Ivabradine improved regional contractility in the stunned myocardium
,whereas with atenolol it deteriorated further due to negative inotropism. These
results may have important clinical implications in LV systolic dysfunctions.60
Pharmacokinetics:
1.Absorption :
Ivabradine is rapidly and almost completely absorbed after oral administration
.With a peak plasma level reached in about one hour under fasting conditions and an
effective half life of 11 hours. The total clearance is around 400mL/min in patients
55
and the absolute bioavailability of the film-coated tablets is around 40%, due to
first-pass effect in the gut and liver.61
2.Distribution :
Ivabradine is approximately 70% plasma protein bound.
3.Plasma half life :
Half life of ivabradine is about 2 hrs .
4.Metabolism :
The N-desmethylated derivative of ivabradine has been identified as the main
active metabolite in humans. This active metabolite is responsible for the initial
bradycardic effect, whereas the parent compound is responsible for the duration of
action. Ivabradine is extensively metabolised by the liver and the gut, being oxidised
by the cytochrome CYP3A4 and it is also a very weak inhibitor of this cytochrome.
5.Interactions :
CYP3A4 inhibitors and inducers may interact with ivabradine and influence its
metabolism and pharmacokinetics to a clinically significant extent. Drug use with
strong inhibitors of CYP3A4 (ketoconazole eryhthromycin, diltiazem or verapamil)
is contraindicated as this may lead to a significant plasma exposure of ivabradine
possibly resulting in risk of excessive bradycardia. The CYP3A4 inducer Hypericum
perforatum was shown to reduce plasma concentration and availability of ivabradine
and S18982 following co-administration with ivabradine in normal healthy
volunteers. A short time was observed and lower apparent terminal half-life values,
consistent with an induction of ivabradine metabolism.62
6.Excretion :
The total clearance is around 400mL/min.
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 Special populations:
Ivabradine does not reliably slow heart rate during atrial fibrillation or other atrial
tachycardia or in patients dependent on cardiac pacemakers. Therefore, it is only
indicated for treatment in patients where heart rate is controlled by the sinus node.
The use of ivabradine is contra-indicated in heart failure patients with NYHA
functional classification III&IV and in patients with asymptomatic left ventricular
dysfunction or stroke patients.63
 Dosing and titration :
Ivabradine is available in tablet form at 5 and 7.5mg. The usual recommended
starting dose is 5 mg twice-daily, in the morning and evenings during meals. After
three to four weeks of treatment, the dose may be increased to 7.5 mg twice-daily
depending on the therapeutic response. If, during treatment, heart rate decreases
persistently below 50 beats per minute (bpm) at rest or the patient experiences
symptoms related to bradycardia such as dizziness, fatigue or hypotension, the dose
must be titrated downward including the possible dose of 2.5 mg twice-daily (one
half 5 mg tablet twice daily). Treatment must be discontinued if heart rate below 50
bpm or symptoms of bradycardia persist.64
 Coadministration with other drugs:
Concomitant use of ivabradine with heart rate reducing calcium channel blockers
such as verapamil or diltiazem is not recommended. Ivabradine should also not be
used in combination with QT prolonging agents. There is no contraindication in
taking ivabradine in combination with other cardiovascular drugs, including anti-
platelet agents , statins,angiotensin-converting enzymes and beta blockers.
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 Safety and tolerability:
Ivabradine has a good safety profile and well tolerated.Sinus bradycardia is an
expected pharmacological effect of ivabradine and is proportional to the resting
heart rate. Slowing the heart rate by ivabradine is associated with prolongation of
the QT interval in a dose-dependent manner .It occurs at rest and during exercise
due to the slowing of the sinus node discharge by selective inhibition of the If
current. There is no association of sinus bradycardia with aggravation of other
arrhythmias. There is no rebound effect with drug cessation or pharmacological
tolerance with long-term use.There  is mild visual symptoms being the most widely
reported side-effects.65 The visual symptoms associated with ivabradine are due to
the action of ivabradine on retinal ion channels (If current), which belong to the
same family as those responsible for the If current in the sino-atrial node. In current
clinical trials of ivabradine, visual symptoms (mainly phosphenes)  are reported in a
small proportion of patients. These symptoms are generally mild and resolved
spontaneously during or after treatment.47
STUDIES RELATED TO IVABRADINE :
1. A meta-analysis conducted in Cardiovascular Division, King's College
London, British Heart Foundation Centre, London identified Ivabradine
significantly improves cardiac function in patients with ischemic heart
disease . This was the first time to evaluate the benefits of Ivabradine in
patients with IHD using meta-analysis. According to that study, Ivabradine
can significantly improve the left ventricular function. More impressively,
LVEF (WMD 2.669%; 95% CI 1.655 to 3.684; p < 0.01) was statistically
improved no matter if patients were followed up for shorter or longer than
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three months, enrolling in higher quality research or lower, and whether β-
blockers were used concurrently or not .66
2. A 4-month, randomized, placebo-controlled trial conducted in Montreal and
Danderyd Hospital, Stockholm, Sweden explained the efficacy of the If
current inhibitor ivabradine in patients with chronic stable angina receiving
beta-blocker therapy. Ivabradine was superior to placebo for all exercise test
criteria at 4 months (P . 0.001 for all) and 2 months (P-values between 0.001
and 0.018). Ivabradine in combination with atenolol was well
tolerated.According to that study ,total exercise duration at 4 months was
increased by (24.3+65.3 s) in the ivabradine group, compared with
(7.7+63.8)with placebo (P < 0.001). 67
3. Jean-Claude Tardif, Ian Ford conducted a study on efficacy of ivabradine, a
new selective If inhibitor, compared with atenolol in patients with chronic
stable anginaDiseasePatients underwent treadmill exercise tests at
randomization (M0) and after 4 (M1) and 16 (M4) weeks of therapy.
Increases in total exercise duration(TED) at trough at M4 were 86.8+129.0
and 91.7+118.8 s with ivabradine 7.5 and 10 mg, respectively and 78.8+133.4
with atenolol 100 mg.68
4. A study conducted in Dubai Heart Center, Division of Cardiology identified
the Short‑Term Effects of Ivabradine in Patients with Chronic Stable
Ischemic Heart Disease .After 4 months of treatment, the heart rate was
significantly reduced from an average of 82 ± 8 to 68 ± 6 bpm (P < 0.001).
The reduction in heart rate was accompanied by a significant improvement in
functional capacity (score 3.5 ± 0.9 to 4.7 ± 0.7, P < 0.001) and angina
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classification.69
5. University of Medicine and Pharmacy, Bucharest Romania conducted a open
–label, randomized trial on Ivabradine Versus Beta-Blockers in Patients with
Conduction Abnormalities or Left Ventricular Dysfunction Undergoing
Coronary Artery Bypass Grafting. The rates of 30-day mortality were lower
in the combined therapy group (2.8%) versus metoprolol or ivabradine
monotherapy groups (3.8% in each monotherapy group). The overall quality
of life was better in ivabradine groups. Ivabradine-treated patients had
shortened hospital stay.70
With the above extensive literature review , as there is handful of studies
related to  efficacy and safety of ivabradine and atenolol in patients with IHD, this
study was designed to assess the anti-anginal and anti-ischemic efficacy and safety of
ivabradine as an add-on to atenolol in patients with chronic stable ischemic heart
disease.
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AIM OF THE STUDY
To evaluate the efficacy and safety of  Ivabradine as an add-on to atenolol in patients
with chronic stable ischemic heart disease prospectively .
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METHODOLOGY
STUDY TYPE:
Interventional  study
STUDY DESIGN:
Open label ,prospective clinical study .
STUDY PERIOD:
April 2014 to May 2015.
STUDY DURATION :
Three months .
STUDY CENTRE:
Single centered study conducted in the Out patient  Department of Cardiology
,Tirunelveli Medical College Hospital , Tirunelveli.
STUDY SAMPLE:
50 patients attending cardiology OPD receiving anti anginal medication for
chronic stable ischemic heart disease.
INCLUSION CRITERIA:
 Patients with age of >18 to <80 years .
 Patients of both sexes.
 Patients with history of chronic stable ischemic heart disease
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 Patients in Canadian Cardiac Society angina pectoris class 1,2,3 and 4.
 Patients with heart rate in sinus rhythm of atleast > 80 beats per minute.
 Patients should be on  oral tab. Atenolol for ischemic heart disease.
EXCLUSION CRITERIA:
 Patients with age group of below 18 yrs to more than 80 yrs .
 Patients with heart rate  of  < 80 beats per minute.
 Patients with H/O of hypotension , BP < 90/50 mmhg(in both the upper limbs
either in the sitting or standing posture).
 Patients with recent or acute attack of  myocardial infarction.
 Patients with  signs and symptoms of acute decompensated heart failure .
 Patients with evidence of  moderate to severe heart block.
 Patients not taking oral tab.Atenolol for ischemic heart disease.
 Patients with symptomatic liver dysfunction or renal impairment.
 Patients with H/O pregnancy and lactation.
 Known hypersensitivity to  study drugs .
 Patients not on sinus rhythm /other types of arrhythmia
 Patients taking anti- arrhythmic drugs
 Patients taking drugs with enzyme inducing and inhibiting properties.
WITHDRAWAL CRITERIA:
 Non compliance with protocol
 Protocol deviation
 Request for withdrawal by the patients
 Heart rate <80 bpm while on medication.
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 Adverse effects( decision about withdrawal from the study made either by
patients or investigator).
ETHICAL CONSIDERATIONS :
Approval from Institutional Ethical Committee  of Tirunelveli Medical College
Hospital was obtained, before starting the clinical study. Written informed consent
was obtained in local vernacular language from every patient  before enrollment .
SCHEDULE OF STUDY VISIT :
a)Screening and recruitment:
The subjects were enrolled based on the inclusion criteria after screening. During
enrollment clinical assessment and the following baseline investigations were done.
 Blood investigations: Hemoglobin,differential WBC count, ESR, bleeding time
and clotting time were done in a blood sample using biochemical automated
analyser.
 Blood sugar, urea  and creatinine and serum electrolytes were measured in a
blood sample using automated analyser.
 Liver function tests including ALT,AST ,total bilirubin ,direct and indirect
bilirubin were measured in a blood sample.
 Baseline heart rate was measured by taking 12 lead electrocardiography.
 Baseline left ventricular  ejection fraction (LVEF) (%)was assessed by
echocardiogram.
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LVEF    =
–
Normal     >60% male &
>55% female.
 Baseline left ventricular systolic function  was assessed by echocardiogram.
Grading of left ventricular (LV)systolic  dysfunction based on  LVEF  as
follows:71
No  dysfunction             = LVEF > 45%
Mild  dysfunction          =  LVEF 45-54%
Moderate   dysfunction   =  LVEF 44-30%
Severe dysfunction       =  LVEF < 30%
 Baseline blood pressure was measured manually after 5 minutes of rest twice
atleast 2 minutes apart in right arm in sitting posture with the cuff at heart level
using sphygmomanometer.
 Baseline  Canadian class of angina grading was assessed according to the
clinical symptoms and signs.
b) Treatment protocol :
Patients received the drug as follows :
Tab.Ivabradine  5-7.5 mg  OD for 3 months.
After screening, ivabradine  5 mg once daily was prescribed to all patients who were
included in this clinical study . Patient’s evaluation at baseline was used as the control.
The study patients were reviewed every 2 weeks. Dose of ivabradine was titrated  upto
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7.5 mg once daily according to the heart rate(if still >100bpm) after 4 weeks of the
study.Ivabradine was given orally once daily for a duration of 3 months for each
patient. Also the patients were given a diary to note down the adverse events. The
tablets were provided for 15 days only. Then the patients were instructed to report to
the out patient department after 2 weeks along with the diary and empty strips to
collect the drugs. During each visit heart rate was monitored by taking ECG.  At the
end of 1st and 3rd month ,left ventricular function and ejection fraction were measured
by using echocardiogram. Ivabradine tablets(ivanode)5mg and 7.5 mg provided by
pinnacle pharmaceuticals.
c)Quality of life assessed with SAQ:
For measuring specific quality of life, SAQ questionnaire72 (Appendix)was used at the
end of 3 months of study period. This questionnaire included (19 phrases) which
measure five dimensions of coronary artery diseases:
 physical constraint (9 phrases)
 angina stability (1 question)
 angina severity (2 phrases)
 treatment satisfaction (4 phrases) and
 perceiving disease (3 questions).
The questions are in 5 and 6 Likert form. Scores on each scale range from 1 to 5 (or)
6.  It is then converted from 0 to 100 using the following calculation.73
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Zero is the worst and one hundred is the best situation in the considered scale.
d) Follow up:
Follow up was done after 15,30,45,60,75 and 90 days ,clinical examinations
including vital signs such as blood pressure, heart rate were measured .At the end of
1stand 3rd month, laboratory investigations such as blood Hb gm%,total count ,ESR
,serum electrolytes,LFT ,blood sugar,urea and creatinine were performed. Also
echocardiogram and Canadian class of angina grading based on clinical improvement
in signs and symptoms was done .
EFFICACY PARAMETERS:
PRIMARY ENDPOINT:
 Reduction in resting heart rate using 12 lead ECG .
 Improvement in Canadian cardiovascular  society (CCS)class of angina
grading.
SECONDARY ENDPOINT:
 Improvement in ejection fraction(EF) using echocardiography.
 Improvement in left ventricular function(LVF) using echocardiography.
 Improvement in quality of life score using SAQ .
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SAFETY ASSESSMENTS:
Any adverse events reported by the subject or noted by the clinician during  each
follow up visit was recorded .If continuation of the drug was considered harmful, the
subject could be withdrawn from the study.Any adverse event was considered as
serious if it was fatal, life threatening, disabling or if it prolonged hospitalization of
the subject.
COMPLIANCE:
Compliance was assessed by reduction in heart rate and pill count methods.
STATISTICAL ANALYSIS:
Statistical analysis was performed with the help of statistical package
SPSS( Statistical package analysis package for the social sciences )version 11.
 Baseline characteristics of the study patients  were tabulated by descriptive
statistics(mean and standard deviation ) and frequency table .
 The analysis of primary parameters were done by using “Student paired t test”
at the end of 1 and 3 months before and after giving Ivabradine.
 The analysis of secondary parameters like left ventricular function and ejection
fraction improvement were done by using “Student paired t test” at the end of 1
and 3 months before and after giving Ivabradine
 The quality of life scoring was done by using SAQ questionnaire and compared
with CCS class of grade of angina by using ANCOVA .
 The adverse drug reactions were tabulated and  expressed in percentage.
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CONSORT DIAGRAM
Patients screened n=60
Patients enrolled n=55
T.Ivabradine 5 mg given
nn=55
T.Ivabradine n=50
At baseline blood
investigations,ECG
and ECHO  were taken
.
ECG,ECHO
n=5 withdrawn :
2=noncompliance
3=HR<70bpm
At the end of 1 month
blood
investigations,ECG
and ECHO taken
At the end of 3
months blood
investigations,ECG
and ECHO taken
Completed study n=50
Inclusion criteria not
satisfied n=5
69
RESULTS
In the period of 1 year from April 2014 to May 2015 ,60 cases of chronic stable
ischemic heart disease already on tab.atenolol ,attending the outpatient Department of
Cardiology were screened for their eligibility based on the inclusion and exclusion
criteria .Among the 60  patients , 55 patients were enrolled for the study and given
tab.Ivabradine once daily orally and 5 patients were withdrawn from the study due to
non compliance and reduction in heart rate below 70 bpm. At the end of 1 month,
those 50 patients continued the study and completed the study.
The demographic data concerning the patient’s age, sex, weight, vitals,
hemodynamic and laboratory parameters were statistically assessed at the baseline.
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TABLE -1
BASELINE CHARACTERISTICS
Table 1 shows the baseline characteristics of the study population (mean/SD).
BASELINE  PARAMETERS TAB.IVABRADINE (n=50)
Age(yrs)
(mean/SD)
56.06 ± 11.21
Gender (n)
Male 38
12Female
Heart Rate (bpm)
(mean/SD)
93.08± 11.67
Ejection Fraction (%)
(mean/SD)
41.36±6.23
Canadian cardiovascular
class(n)
0          1            2                3
0        80           14               6
Left ventricular dysfunction (n) Mild Moderate          Severe
20 70                   10
Hb (%) (mean/SD)
WBC (cells/cumm)
(mean/SD)
ESR (mm/hr)
(mean/SD)
13.47 ± 1.95
8873±1311.88
15.17±1.58
Blood sugar (gms%)
(mean/SD)
168.6±64.5303
serum Na+(meq/L)
(mean/SD)
139.18±3.29
serum K+(meq/L)
(mean/SD)
4.2±0.3
Alkaline phosphatase(IU/L)
(mean/SD)
74.24+30.81
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FIGURE 8
AGE DISTRIBUTION OF THE PATIENTS IN THE STUDY
 Figure 8 shows  that the age  distribution  of  chronic stable IHD patients
involved in this study.
 Maximum number of patients (19 patients) were  in the  age group of  51- 60
yrs.
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FIGURE 9
SEX DISTRIBUTION OF THE PATIENTS IN THE STUDY
 Figure 9 is a pictoral representation of sex distribution of study patients.
 76% patients were male and 24% patients were female .
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FIGURE 10
NUMBER OF STUDY PATIENTS WITH CO-MORBID MEDICAL
CONDITIONS
 Figure 10 shows graphical representation  no.of study patients with co- morbid
medical conditions .
 Among 50 patients , 19 patients had hypertension and 19 patients had
hypertension as well as diabetes .
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PRIMARY EFFICACY PARAMETERS
TABLE  2
REDUCTION IN HEART RATE AT THE END OF 1 & 3 MONTHS
COMPARED WITH BASELINE
* p value <0.05, statistically significant at the end of first and third month.
 Shown in Table 2 is efficacy of Ivabradine in reducing the heart rate at  the end
of  1month (86.60±9.16) and at the end of 3 months (81.82±8.37) when
compared with baseline (93.08±11.67).
 Reduction in heart rate at the end of 1 and 3 months after taking Ivabradine was
statistically significant (p<0.0001)
HEART RATE MEAN S.D P VALUE
Base line 93.08 11.67
1month 86.6 9.16 < 0.0001*
3months 81.82 8.37 < 0.0001*
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FIGURE 11
REDUCTION IN HEART RATE AT THE END OF 1 AND 3 MONTHS
COMPARED WITH BASELINE
 Graphical representation of reduction in heart rate before and after taking tablet
Ivabradine
 Reduction in heart rate from baseline (93.08±11.67) to end of the  1st month
(86.60±9.16) and at the end of 3rd month (81.82±8.37).
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TABLE 3
IMPROVEMENT IN CANADIAN CARDIOVASCULAR SOCIETY CLASS OF
ANGINA GRADING
CCS class of angina grade
1 2 3 4
Number
of
Patients
Baseline 0 40 7 3
1 Month 39 8 3 0
3 Months 40 9 1 0
 Table 3 shows improvement in Canadian cardiovascular society class of angina
pectoris grading based on the  clinical signs and symptoms .
 At the baseline 3 patients were in the CCS class of angina grade IV. After
treatment with Ivabradine , none of the patients were in the CCS class of
angina grade IV at the end of 1 &3 months.
 At the baseline 7 patients were in the CCS class of angina grade III. After
treatment with study drug ,patients with CCS class of angina grade III were 3
patients at the end of 1 month and 1 patient at the end of 3 months.
 At the baseline 40 patients were in the CCS class of angina grade II. After
treatment with study drug ,patients with CCS class of angina grade II were 8
patients at the end of 1 month and 9 patients at the end of 3 months.
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FIGURE 12
IMPROVEMENT IN CANADIAN CARDIOVASCULAR SOCIETY GRADING
OF ANGINA PECTORIS
 Graphical representation of improvement of Canadian cardiovascular society
grading (CCS)of angina at the end of 1 and 3 months compared with baseline .
 Blue dotted line in the above graph is the logarithmic trend line of baseline
CCS compared with 1 st month (red dotted line) and 3 rd month (green dotted
line) logarithmic trend lines .
 Based on the comparision of  logarithmic trendline at the baseline with 1 and 3
months Ivabradine showed improvement in CCS class of grade of angina.
0
39 40
0
10
20
30
40
50
1
N
o
 o
f p
a
tie
n
ts
40
78
3
9
1
2 3CCS   Grading
Baseline 1 Month
3
0 0
4
3 Months
78
SECONDARY EFFICACY PARAMETERS
TABLE 4
IMPROVEMENT IN LEFT VENTRICULAR FUNCTION
 Table 4 shows,   study drug  improved  the  left ventricular (LV)function at the
end of 1 and 3 months of treatment when compared with baseline .
 At the baseline  there were 5 patients with  severe LV dysfunction ,35 patients
with moderate LV dysfunction and 10 patients with mild LV dysfunction.
 After treatment with Ivabradine , there were no patients with severe LV
dysfunction at the end of 1 and  3 months when compared with 5 patients at the
baseline.After treatment with study drug patients with moderate LV
dysfunction was reduced to 20 at the end of 1 month and 6 patients at the end
of 3 months when compared with 35 patients at the baseline.
Left ventricular
function
No
dysfunction
Mild
dysfunction
Moderate
dysfunction
Severe
dysfunction
Number
of
patients
Baseline 0 10 35 5
1 Month 0 30 20 0
3 Months 3 41 6 0
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FIGURE 13
IMPROVEMENT IN LEFT VENTRICULAR FUNCTION AT THE END OF
1&3 MONTHS COMPARED WITH BASELINE
 Graphical representation of improvement in left ventricular function at
the baseline ,at the end of 1 and  3 months.
 Blue dotted line in the graph shows logarithmic trend line of left
ventricular function at the baseline .
 Red and green dotted lines show logarithmic trend line of left ventricular
function at the end of 1 and 3 months respectively.
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FIGURE 14
Improvement in ejection fraction %(mean/SD) at the end of 1 & 3 months of
treatment compared with baseline
 Figure 14 shows ejection fraction % (mean and SD) at the end of 1&3 months
compared with baseline .
 After treatment with study drug the improvement in ejection fraction% was
(45.48±5.03) (p<0.001) at the end of one month and ( 49.08±4.17)(p<0.001)
three months compared with the baseline(41.36±6.23).
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TABLE 5
Quality of life score based on SAQ  . Five variables of  angina are  compared with
CCclass of angina
Table 5 shows the quality of life score based on SAQ . It contains five variables . Each
variable(mean/SD) was compared with CCS class of angina and their p value was
statistically not significant. It means all these variables were associated with highest
score of quality of life and they did not show any significant differences in the
different grades of CCS class of angina .
VARIABLES
CCS
class 1
CCS
class 2
CCS
class 3
P
value
Mean S.D Mean S.D Mean S.D
Physical  Constraint 47.5 14.76 44.44 14.12 37.5 0 0.698
Angina Stability 37.5 18.77 47.22 29.16 25 0 0.368
Angina Severity 24.75 10.61 30 12.24 20 0 0.381
Treatment
Satisfaction 42.85 9.22 39.11 12.57 29 0 0.258
Perceiving Disease 30.45 10.43 31.55 9.16 50 0 0.177
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TABLE 6
LABORATORY  PARAMETERS OF THE STUDY POPULATION
 The above table shows the laboratory parameters of study patients at the
baseline ,at the end of 1 month and at the end of 3 months .
 No significant changes were seen in  hemodynamic parameters.
 No significant  elevation in liver enzymes were found during the treatment
period and follow up.
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ADVERSE DRUG REACTIONS
No patients were withdrawn from the study due to adverse drug reactions during the
study period. No serious adverse events were reported in study patients . The most
common adverse drug reactions reported were tabulated .
TABLE 7:
Adverse drug reactions No. of patients
n(%)
Bradyarrythmia 2 (4%)
QT prolongation 1 (2%)
Blurring of vision 1 (2%)
Photopsia 1 (2%)
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DISCUSSION :
Coronary artery disease is the leading cause of morbidity and mortality in world
wide1.Heart rate is a major determinant of cardiac output ,myocardial oxygen demand
and coronary blood flow. High resting heart rate has emerged as a simple but relevant
risk factor for coronary artery disease and heart failure. Pharmacotherapy for IHD is to
reduce the angina attacks by reducing the heart rate. Evidence suggested that many
patients maintain a resting HR ≥ 70/min despite optimal beta blocker therapy74.
Conventional anti-anginal drugs like nitrates ,CCB and K + channel openers could
interact with beta-blockers and  in addition they have negative inotropic activity  . So
we need a better agent which will reduce the heart rate without having negative
inotropic activity and other system involvement .
In recent years, a new drug to reduce HR, Ivabradine has been introduced for
clinical practice by Euro Society of Cardiology .According to the results of the
INITIATIVE trial which compared Ivabradine with atenolol over 4 months in 939
patients with stable angina pectoris and documented coronary artery disease ,
Ivabradine showed non-inferiority in reducing the total exercise duration and exercise
performance and improved performance .75
The mean age of the subjects in our study was 56.06 ± 11.21(table 1). It clearly
showed that  ageing is an important non- modifiable  risk factor for chronic stable
ischemic heart disease .Similarly ,a prospective, follow-up study conducted in Finland
concluded that in both sexes  the CHD risk was largest in the oldest age (50-69yrs)
group.76
85
According to our study, the majority of the study subjects were male patients
76%(figure 9)and males in the community were more prone for ischemic heart disease
than females  . In one study conducted by Peters and Woodwards showed that over a
median follow-up of 6.7 years, 5695 IHD events were documented. Based on the
major risk factors ,the age-adjusted prevalence  was higher in males than females. The
hazard ratio for IHD, comparing men with women, was 1.88 (95% CI 1.54-2.29) in
Asia and 2.14 (95% CI 1.97-2.33) in Australian and New Zealand .77
In our study , significant reduction in heart rate was reported in patients with
CHD during the treatment period was 81.82±8.37(table2) compared with baseline
93.08±11.67 and the p value was significant (<0.001) . Similarly a study conducted by
Nicoline Jochmann and Franziska et al found a significant decrease in heart rate, both
4 hours after the intake of 7.5 mg of ivabradine (median −8 [interquartile range (IQR)
-14 to −4] bpm) and after 4 weeks of twice daily intake (median −10 [IQR-17 to −5]
bpm) (p < 0.05).78
Thus for preventing and treating the further anginal attacks reducing the heart
rate is the important key factor without producing negative inotropic and lusitropic
effect. Our study drug by acting on the novel specific and selective blocking of  If
current present in the SA node of the right atrial chamber showed significant reduction
in heart rate(figure 11)
In this study , treatment with ivabradine improved the CCS class of angina
grading compared with baseline.Those patients at the grade III and IV at baseline were
moved to grade I and II over a period of 3 months. At the baseline 3 patients were in
the CCS class of angina grade IV . After treatment with Ivabradine , none of the
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patients in the CCS class of angina grade IV at the end of 1 &3 months. At the
baseline 7 patients were in the CCS class of angina grade III. After treatment with
study drug ,patients with CCS class of angina grade III were 3 patients at the end of 1
month and 1 patient at the end of 3 months.At the baseline 40 patients were in the
CCS class of angina grade II. After treatment with study drug ,patients with CCS class
of angina grade II were 8 patients at the end of 1 month and 9 patients at the end of 3
months. Similarly , in  a post hoc analysis of BEAUTIFUL Trial suggested that the
effect of adding Ivabradine to the conventional beta-blocker (90%) improved the CCS
class of grade of angina .79
In this study , Ivabradine improved the left ventricular function based on LVEF
compared with baseline . After treatment with Ivabradine , there were no patients with
severe LV dysfunction at the end of 1 and  3 months when compared with 5 patients at
the baseline. After treatment ,moderate LV dysfunction was reduced to 20 patients at
the end of 1 month and 6 patients at the end of 3 months when compared with 35
patients at the baseline.
Like wise, after giving Ivabradine showed there was significant  improvement
(p<0.001) in ejection fraction%. It was 45.48±5.03 at the end of one month and
49.08±4.17 at the end of three months compared with the baseline(41.36±6.23).A
SHIFT echocardiography substudy was conducted by Montreal Heart Institute which
showed that LVEF was increased by (2.4 ± 7.7%) in the Ivabradine group but  LVEF
was unchanged in the placebo group (−0.1 ± 8.0%). More than a third (36%) of the
patients in the ivabradine group had ≥5% increase in LVEF vs. less than a quarter
(23%) of the placebo group (P= 0.003).80
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In our study , Ivabradine improved the quality of life score and each variables in
the SAQ was compared with CCS class of angina grade and showed that all these
variables were associated with highest score of quality of life . Similar to this  result ,
a study conducted by Taheri Kharame et al , which showed highest score regarding
treatment satisfaction (66.34±17.32) and higher quality of life regarding angina
stability and perceiving disease in patients who received Ivabradine.81
In our study ,Ivabradine did not influence the blood pressure. The routine
hematological and biochemical evaluations did not show any significant difference in
the pre–post values (p>0.05). A study conducted by Aditi Chaturvedi, Yogendra Singh
et al. showed  that Hb, LFTs, RFTs, serum electrolytes and RBS done at baseline and
after 8 weeks of use of the Ivabradine  did not show any significant difference p>0.05
(using the paired “t” test)82.
In our study, Ivabradine related adverse drug reactions reported were
bradyarrythmia, QT prolongation and visual disturbances like blurring of vision and
photopsia. Study conducted by Borer et al.83,Tardif et al.84 and  Ruzyllo et al.85
showed similar adverse drug reactions.These reactions were considered to be  mild
and abated on its own after treatment period. But no patients were withdrawn from the
study due to adverse drug reactions and no patients experienced serious adverse drug
reactions .
Efficacy of Ivabradine by assessing the reduction in heart rate, left ventricular
function and ejection fraction improvement in patients with chronic stable angina
were the strength of this study . Small sample size and  lack of long term follow up
were the limitations of this study.
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Thus the present study showed that Ivabradine causes reduction in HR,
improvement in CCS class of angina grading , left ventricular dysfunction , ejection
fraction and quality of life. Therefore the study drug, Ivabradine is safe and effective
when given along with atenolol in treating chronic stable ischemic heart disease.
Further studies are needed with larger sample size and long term follow up.
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CONCLUSION
Based on the results of our study , we conclude that
Ivabradine is safe and  effective in preventing and treating further anginal attacks in
patients with chronic stable ischemic heart disease  already on atenolol therapy.
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EFFICACY AND SAFETY OF IVABRADINE AS AN ADD-ON TO ATENOLOL
IN PATIENTS WITH CHRONIC STABLE ISCHEMIC HEART DISEASE
ABSTRACT:
INTRODUCTION:
Coronary artery disease is the leading cause of morbidity and mortality. Heart rate is
the important key factor for determining the cardiac output ,myocardial oxygen demand
and coronary blood flow . By the year 2020 , WHO predicts 13.2% death due to CAD . In
india , 11% of urban population and 7% of the rural population had the prevalence of
IHD. Reduction in heart rate is the main stay of treatment for preventing and treating the
cardiovascular complications due to IHD. Pharmacotherapy of IHD are the conventional
drugs like nitrates, beta blockers and calcium channel blockers . Due to the interactions
with other drugs and adverse effects of the conventional drugs ,the management of IHD
focused on novel targets . Ivabradine is a novel specific and selective If current inhibitor
which slows the diastolic depolarization by acting on the SA node.
OBJECTIVE :
Efficacy and safety of Ivabradine as an add-on to atenolol in patients with chronic
stable ischemic heart disease .
MATERIALS AND METHODS:
Interventional ,open label ,prospective clinical study was done over a period of 1
year (April 2014 to May 2015).Single centered study conducted in 50 patients in the Out
patient Department of cardiology ,Tirunelveli Medical College Hospital ,
Tirunelveli.Primary endpoints noted were reduction in resting heart rate using 12 lead
ECG and improvement in Canadian cardiovascular  society (CCS)class of angina
grading. Secondary end points were improvement in ejection fraction(EF) using
echocardiography,improvement in left ventricular function(LVF) using echocardiography
and improvement in quality of life score using SAQ .
RESULTS:
The demographic data concerning the patient’s age, sex, weight, vitals, hemodynamic
and laboratory parameters were statistically assessed at the baseline. Ivabradine in
reducing the heart rate at  the end of  1month (86.60±9.16) (p<0.0001) and at the end of
3 months (81.82±8.37)( p<0.0001) when compared with baseline (93.08±11.67). CCS
class of grade of angina also improved at the end of one month and 3 months compared
with baseline .Grade IV ( 3 – 0 - 0), grade III(7  3 -1) and grade II( 40 -8 - 9).
Study drug improved the LV dysfunction . After treatment with tab.Ivabradine , there
were no patients with severe LV dysfunction at the end of 1 and  3 months when
compared with 5 patients at the baseline.After treatment with study drug, moderate LV
dysfunction was reduced to 20 patients at the end of 1 month and 6 patients at the end of
3 months when compared with 35 patients at the baseline. After treatment with study
drug the improvement in ejection fraction% was( 45.48±5.03) (p<0.001) at the end of one
month and (49.08±4.17) (p<0.001) three months compared with the
baseline(41.36±6.23). Improvement in quality of life also assessed with SAQ
questionnaire . Adverse drug reactions reported during the study was mild and no patients
were withdrawn from the study due to adverse drug reactions and no patients experienced
serious adverse drug reactions.
CONCLUSION :
Ivabradine is safe and  effective in preventing and treating further anginal attacks in
patients with chronic stable ischemic heart disease  already on atenolol therapy.
KEYWORDS: Ivabradine, If current ,Ischemic Heart Disease, Heart Rate, Angina,
Ejection fraction .
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